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8  | General introduction
Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease, after Alzheimer’s 
disease, with an estimated prevalence of 0.3% of the entire population in industrialised countries.1 
In the Rotterdam study, a prospective population based study of people aged 55 or more years in a 
suburb of Rotterdam, an incidence rate of 1.7 per 1000 person years was found , whereas in people 
over 85 years this number increased to 4.3 per 1000 person years.2
Even though it is nowadays recognized that many nonmotor domains are also involved in PD, 
the clinical diagnosis of PD is still based on motor symptoms only: The definition of probable PD 
according to The United Kingdom Parkinson’s Disease Society Brain Bank Criteria requires the 
presence of bradykinesia and at least one of the following motor symptoms: resting tremor, rigidity, 
or postural instability.3,4 The nonmotor symptoms that are involved in PD include, but are not limited 
to, olfactory dysfunction, cognitive impairment, depressive symptoms, sleep problems, daytime 
sleepiness, autonomic dysfunction, psychotic symptoms, and pain.5 Olfactory dysfunction is one of 
the first PD features6 to manifest and seems to be a feature unrelated to other impairment domains 
of PD.7 Cognitive impairment, including executive dysfunction as well as memory, attention, and 
visuospatial problems, is frequently present, even in the early stages of the disease.8 The point 
prevalence of dementia in PD in population based studies is approximately 30%, whereas the 
cumulative prevalence may rise to 75% in patients with long disease duration.9 Depression is a 
common feature of PD, although the reported prevalence rates vary widely. Prevalence rates of 
17% for major depressive disorder and 35% for depressive symptoms were estimated by meta-
analyses.10 The basis of depression is suggested to be related to the disease process, rather than 
being a secondary response to a chronic disease.5 Sleeping problems mainly concern difficulties with 
maintaining sleep and often occur together with depressive symptoms. However, daytime sleepiness 
is more prevalent than nighttime sleeping problems and has an obvious impact on daily activities.11 
A wide range of autonomic symptoms is present in PD, including problems with cardiovascular, 
thermoregulatory, pupillomotor, sexual, urinary and gastrointestinal functioning, with the latter 
two domains showing the greatest difference in prevalence as compared to control subjects.12 In a 
longitudinal multicenter study it was shown that in patients surviving for 15 years or more, falls, autonomic 
disturbance, neuropsychiatric complications, and dementia were common features. All of these features 
are not responsive to levodopa, which is the most commonly prescribed medication for the treatment of 
PD’s motor symptoms.13 Additionally, motor fluctuations and dyskinesias may emerge as complications 
of the dopaminergic treatment used to alleviate some of the motor disturbances of the disease. The 
clinical spectrum of PD is no longer considered to be restricted to movement disoderders, but is nowadays 
characterized by a broad spectrum of motor and nonmotor features. 
Pathogenesis
A definite diagnosis of PD requires post-mortem findings of neuronal loss and depigmentation of 
substantia nigra as well as Lewy bodies in the brain stem.3 Lewy bodies and Lewy neurites are 
abnormal filamentous protein inclusions in neurons and neurites respectively, but inclusions may also 
occur in glia and presynaptic terminals. A major component of the Lewy bodies and Lewy neurites is 
aggregated or misfolded alphasynuclein.14
For a long time, PD has been considered a clinicopathologic entity caused by selective dopaminergic 
cell loss in the substantia nigra. However, this view has changed dramatically, since pathologic and 
genetic data have emphasized the important role for alphasynuclein in PD. The widespread presence 
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of alphasynuclein pathology in the peripheral and central nervous system has positioned PD as a 
multi-system disorder, involving not only the dopaminergic system, but also the noradrenergic, 
serotonergic, cholinergic, and other central neurotransmitter systems.15,16
Braak and colleagues have proposed a six-stage system, indicating a topographically caudo-rostral 
predictable sequence of intracerebral formation of abnormal proteinaceous Lewy bodies and Lewy 
neurites.17 The pre-clinical stages 1 and 2 are characterized by pathology confined to the olfactory bulb 
and the anterior olfactory nucleus, as well as the lower brainstem. Subsequently, degeneration of the 
substantia nigra, ventral tegmental area, nucleus basalis of Meynert, and other nuclear grays of the 
basal midbrain and forebrain occurs in stages 3-4. Stages 5-6 are characterized by severe involvement 
of the brain, including the limbic structures and the neocortex.17 However, in retrospective clinico-
pathologic studies, up to 43% of the cases did not follow the proposed caudo-rostral progression 
patterns of Lewy body pathology as suggested by Braak and colleagues.14 Furthermore, relationships 
between the Braak stages and clinical severity of PD could not be confirmed.14 Recently, a new 
unified staging system was proposed based on research on post mortem data, allowing classification 
not specifically for PD, but for all Lewy body disorders.18 Other Lewy body disorders that were 
studied include dementia with Lewy bodies, incidental Lewy body disease, and Alzheimer’s disease 
with sparse predominantly limbic Lewy bodies. In this new staging system, presence or absence of 
alphasynucleinopathy is scored in four stages. In the first stage, alphasynucleinopathy is confined to 
the olfactory bulb. In the second stage, alphasynucleinopathy is either dominant in the brainstem (IIa) 
or the in the limbic structures (amygdala; IIb). In stage III both the brainstem and limbic structures are 
affected, while in stage IV the neocortical area is involved as well.18 With the new staging system, 
an agreement of over 80% was found between clinical classification of patients and pathological 
findings. PD patients in successive stages showed a stepwise worsening in terms of substantia nigra 
pigmented neuron loss, cognitive functioning and motor impairment.18,19 Nevertheless, the role of 
Lewy bodies is still debated. Lewy bodies have been proposed to be pathogenic, but others have 
argued that they are protective or merely incidental.14,15,20 Results of a study on a Drosophila model 
suggested that Lewy bodies might be a protective response controlling neurotoxicity.21 Furthermore, 
Lewy bodies have not been found in all patients with the PD phenotype; some patients had tau 
aggregates (common in Alzheimer’s disease) or no aggregates at all. 14,15,20 Hence the predictive 
validity of protein aggregates is doubtful and the two facts together suggest that Lewy bodies may 
not have a direct pathogenic role in the neurodegenerative process.14,15,20 It has been suggested that 
the formation of Lewy bodies is one of several response patterns to the pathologic process, and 
that the actual cell loss or the associated synaptic dysfunction might be a more suitable marker.22 
Nevertheless, Lewy bodies might still be helpful markers of the neurodegenerative process by 
reflecting changes in the cellular environment, thereby indicating affected neurons and because of 
this possibly elucidating the pathogenic mechanism.14,20
Current hypotheses of the pathogenic mechanism in PD include mitochondrial dysfunction, oxidative 
stress, and protein aggregation. These pathways may also interact in the pathogenesis of PD. 23-25 
Mitochondrial dysfunction was linked to PD after the finding of mitochondrial complex I deficiency 
in the substantia nigra.24,25 Inhibition of mitochondrial complex I can impair oxidative phosphorilation 
and can thereby increase free radical generation. Conversely, mitochondrial function may also be 
negatively influenced by oxidative stress.24,25 In eukaryocitic cells, the quality of proteins is monitored, 
and misfolded proteins are refolded. If damaged proteins cannot be repaired, they are normally cleared 
by the so-called ubiquitin-proteasome system. Mitochondrial defects and free radicals can negatively 
affect the function of this ubiquitin-proteasome system. Defects in the ubiquitin-proteasome system or 
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excessive production of misfolded proteins result in accumulation of misfolded proteins with detrimental 
effects on the cell function and usually subsequent cell death.23-25 
Aetiology
Genetic factors
For a long time, PD was thought to be a sporadic disease. However, with the identification of 
mutations in several genes that can cause both familial and sporadic PD, the role of genetic factors 
in the aetiology in PD is gradually becoming more important. Although a positive family history of 
PD was previously considered an exclusion criterion for the diagnosis of PD, this is no longer the 
case.22,26 Still, 90% of the cases is considered sporadic PD.1 In the PROfiling PARKinson’s disease 
(PROPARK) cohort (described in more detail below) known genetic variations were found in only 4% 
of the patients.27 
To date, dominant inherited mutations have been identified in two genes, namely the alphasynuclein 
(SNCA) gene and the leucine rich repeat kinase 2 (LRRK2) gene.
Mutations in the SNCA gene (PARK1, PARK4) may lead to amino acid changes, which in turn lead 
to accumulation and aggregation of alphasynuclein. The clinical phenotype is characterized by a 
progressive disease that is responsive to levodopa and which is associated with cognitive decline 
and autonomic dysfunction. The age-at-onset ranges from 38 to 65 years. Patients with SNCA 
triplications have a more rapid progression and a younger age-at-onset.26,28 
Mutations in the LRRK2 (PARK8) gene are the most common cause of autosomal-dominantly inherited 
PD. Phenotypic characteristics are highly variable and the age-at-onset ranges from 50 to 70 years.26 
The associated pathology is variable as well: in cases with mutations the typical Lewy body disease 
has been found, but also tau-aggregates, and nigral degeneration without protein aggregations. It 
is still not clear how LRRK2 mutations lead to neurodegeneration.26,28 
Several recessive genes have been identified, that are related to early onset parkinsonism and 
include Parkin (PARK2), PTEN –induced kinase 1 (PINK1; PARK6) and DJ1 (PARK7). 
Parkin is related to the ubiquitin-proteasome system. It attaches ubiquitin to damaged proteins 
as a signal for degradation, which is impeded by mutations in Parkin. Consequently, the function 
of the ubiquitin-proteasome system is disrupted.24 Patients with Parkin mutations often present 
with dystonia, motor fluctuations, and dyskinesias. Patients are responsive to low doses of 
levodopa and have a slow disease progression. The age-at-onset is around 30 years.26,28
PINK1 mutations are related to mitochondrial dysfunction and oxidative stress. PINK1 and 
Parkin may act in a common pathway.24,28 The phenotype of patients with PINK1 mutations is 
also characterized by a response to low doses of levodopa, a slow disease progression, rapid 
development of dyskinesias, dystonia and an age-at-onset between 20 and 40 years. Depression 
and anxiety are common features in PINK1-associated PD. 26,29
Mutations of DJ1 cause an increased susceptibility to oxidative stress and are related to 
mitochondrial dysfunction. Wild type DJ1 inhibits aggregation of alphasynuclein, whereas this 
effect is lost with the DJ1 mutation.24,28 The phenotypic expression of this mutation is slow 
disease progression, psychiatric disturbance, dystonia, and an age-at-onset between 20 and 40 
years.26,29
Furthermore, there are several known genes and polymorphisms that are not exclusively present in 
PD patients, yet may increase the susceptibility for PD or specific PD features. One of these genes 
Opmaak 2.indd   10 02-10-12   18:37
Chapter 1  |  11
is the glucocerebrosidase (GBA) gene, known to cause Gaucher disease; PD patients were found 
to have a five-fold increased risk for a mutation in the GBA gene as compared to controls. How 
mutations in this gene contribute to the pathogenesis of PD, and whether mutations are associated 
with specific phenotypic characteristics, needs to be further examined.30,31 
Nongenetic factors
The identification of drug-induced parkinsonism following ingestion of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) raised awareness of the potential role of environmental factors in the 
aetiology of PD.32,33 Since then, several environmental factors have been suggested to increase or 
decrease the risk of developing PD. Aging, male gender, personality traits, drinking well water, 
head trauma, physical and emotional stress, are reported factors that may increase the risk of PD. 
Smoking, caffeine intake, use of some NSAID’s, an elevated level of uric acid are reported factors 
that may decrease the risk of PD.22,32 However, studies on the relation between these factors and PD 
showed inconsistent results. Further, the results of prospectively designed studies may be influenced 
by a phenomenon that is called ‘reversed causality’: in the pre-symptomatic period patients may have 
changed their behaviour (for instance food intake) as a consequence of the disease. Since the exact 
duration of the preclinical period is unknown, risk factors may erroneously be thought to have an 
aetiological role. Hitherto, older age and smoking habits respectively, are the only factors that have 
consistently been found to increase or decrease the risk of PD.1
In conclusion, PD can be explained by well-defined genetic or environmental causes in only a minority 
of patients, whereas in the majority of patients multiple interactions between (susceptibility) genes 
and nongenetic factors are assumed to contribute to the development of PD. Thus, the aetiology 
of PD is most likely the result of complex interactions between genes, environment, and an aging 
nervous system.1,22,24 
Subtypes of  Parkinson’s disease
In 1888, the clinical heterogeneity of PD was already subject of study. Although patients with 
‘paralysis agitans’ were considered to be characterized by tremor, in one of his lessons Charcot 
presented a patient with PD who did not have tremor. This was one of the reasons why he suggested 
to refer to the disease as ‘Parkinson’s disease’ instead of ‘paralysis agitans’ (‘shaking palsy’); this term 
did not accurately characterize the disease.34 
Clinical heterogeneity of PD is not limited to rigidity and tremor. Compared to tremor dominant 
patients, patients with predominant bradykinesia and rigidity had more severe cognitive impairment 
and depressive symptoms.35-37 A subtype with dominant Postural-Instability-and-Gait-Difficulty (PIGD) 
was found to be associated with cognitive impairment and depression.38-40 Furthermore, PD patients 
may vary in age-at-onset and rate of progression.41 Patients with younger age-at-onset showed a 
slower rate of disease progression,40-42 but more rapidly developed motor complications.42
As PD is characterized by variability both in clinical presentation and in pathological pathways, 
phenotypic differences may represent different underlying pathogenic mechanisms.33,43 Compared 
to the tremor-dominant subtype, the akinetic-rigid subtype was found to have a greater extent of 
neurodegeneration in several neuroanatomical structures, including the substantia nigra, striatum, 
globus pallidus and locus coeruleus,44-46 and was associated with a greater burden of cortical 
Lewy body pathology.47 As described above, some genetic mutations may contribute to a different 
phenotypic expression. 
Heterogeneity influences the power of studies on underlying mechanisms and genetics, since 
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groups with a homogeneous clinical presentation are likely to have stronger pathological coherence 
as well. As a result, there is an increasing awareness of the importance of the identification of 
clinical subtypes. Moreover, the identification of subtypes may have consequences for management 
strategies, since subtypes may differ in disease progression, response to treatment, and vulnerability 
to complications of therapy. 
Methods identifying subtypes
Clinical subtypes have often been defined on the basis of the investigator’s hypotheses. Patients 
were classified according to pre-specified criteria, usually based on the clinical characteristics of 
a single domain, after which differences in other clinical variables were evaluated.41 The potential 
bias inherent to this approach is that less obvious or unexpected patterns may be missed. 
Alternatively, the presence of subtypes can be objectively examined by data-driven methods like 
cluster analysis (CA) without any a priori assumptions with respect to clinical characteristics of 
subtypes. In CA, individuals are classified into groups, rendering small differences within each 
group of patients, but large differences between different groups (figure 1).48 In this so-called 
unsupervised classification, the profiles of subtypes arise from the data without any a priori 
clinical assumptions.
PROfi l ing PARKinson’s disease
The PROPARK study is a longitudinal cohort study, in which 400 patients are profiled on genotype, 
phenotype, disabilities, and global outcomes of health.49 This project started in 2003; during six 
years patients were annually subjected to an extensive standardized assessment, which included 
evaluation of a broad spectrum of PD domains, physical and psychosocial disability, quality of life, 
demographics, family history of PD, and medication use. The measurement instruments were derived 
from a previous project, the SCales for Outcomes in PArkinson’s disease (SCOPA) project, which was 
carried out between 1999 and 2003. The aim of the SCOPA project was to develop rating scales for 
clinically relevant domains of PD. Measurement instruments had to meet prespecified criteria of good 











Figure 1. An example of a scatterplot showing three clusters (A, B, C) with their specific characteristics 
on ‘variable x’ and ‘variable y’.
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Aims of  the thesis
The general objective of this thesis was to identify clinical subtypes in PD by a data-driven approach. 
To this end, we first systematically reviewed the methodology and results of CA studies in PD to gain 
a better understanding of the robustness of identified subtypes and of the methodological issues 
that may influence the results (chapter 2). An important step in establishing subtypes of phenotype 
profiles in PD is to critically select which variables are included in the CA. A comprehensive view of 
domain interrelations as well as their associations with other clinical and nonclinical parameters was 
the first step in a data-driven determination of subtypes. Using the data of the first annual PROPARK 
assessment, we constructed a model of factors that influence health related quality of life (HRQoL) 
in order to evaluate how impairments and disabilities contribute to HRQoL (chapter 3). In chapter 
4, we first applied a confirmatory factor analysis to evaluate the coherency of motor impairments 
as assessed by the SPES/SCOPA rating scale. Subsequently, we studied patterns of coherency in the 
broad spectrum of motor and nonmotor domains (chapter 5). In chapter 6, a model based CA 
was performed in order to identify subtypes in PD that were solely based on motor and nonmotor 
features of the disease, using data of two independent European cohorts. We used a data-driven 
approach and did not define hypotheses in advance, which means that the profile of the subtypes 
arose from the data without any a priori clinical assumptions. Finally, the main conclusions are 
summarized and discussed in chapter 7.
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Abstract
The clinical variability between patients with Parkinson’s disease (PD) may point at the existence 
of subtypes of the disease. Identification of subtypes is important, since a focus on homogeneous 
groups may enhance the chance of success of research on mechanisms of disease and may also lead 
to tailored treatment strategies. Cluster analysis (CA) is an objective method to classify patients into 
subtypes. We systematically reviewed the methodology and results of CA studies in PD to gain a 
better understanding of the robustness of identified subtypes. We found seven studies that fulfilled 
the inclusion criteria. Studies were limited by incomplete reporting and methodological limitations. 
Differences between studies rendered comparisons of the results difficult. However, it appeared 
that studies which applied a comparable design identified similar subtypes. The cluster profiles ‘old 
age-at-onset and rapid disease progression’ and ‘young age-at-onset and slow disease progression’ 
emerged from the majority of studies. Other cluster profiles were less consistent across studies. Future 
studies with a rigorous study design that is standardized with respect to the included variables, data 
processing, and CA technique may advance the knowledge on subtypes in PD.  
Introduction
Parkinson’s disease (PD) is clinically characterized by a broad spectrum of motor and nonmotor 
manifestations.1 There is, however, considerable variability between patients with PD concerning 
the clinical phenotype, which may indicate that there are subtypes of the disease.2 Identification of 
PD subtypes may be important for research on underlying disease mechanisms, since homogeneous 
groups of patients are more likely to share pathological and genetic features. Second, the identification 
of subtypes may ultimately lead to tailored management strategies. 
In 2002, Foltynie et al. explored the concept of heterogeneity in PD from several perspectives, 
including the clinical phenotype. It appeared that on a clinical level, subtypes generally were classified 
according to prespecified or hypothesized criteria that were based on predominant clinical features 
(tremor, bradykinesia/rigidity, postural instability, cognitive impairment), age-at-onset, and rate of 
progression.2 The potential bias inherent to this approach is that less obvious or unexpected patterns 
may be missed. 
When no a priori structure of the data is known, a data-driven method like cluster analysis (CA) may 
be a very suitable method to study subtypes. CA can be used to explore whether individuals can be 
classified into groups in such a way that differences within a group of patients are small, while the 
differences between groups are large.3 In this so-called unsupervised classification, the characteristics 
of the subtypes arise from the data. Next to this apparent advantage, it is important to be aware 
that the results of CA are dependent on choices that are made in the process of analysis, such as 
the variables selected for analysis, the clustering technique and the number of clusters.2,3 In the 
review on heterogeneity by Foltynie et al.2 only one study was reported that explored the existence 
of clinical subtypes in PD by CA, but several other studies have been published since. In the present 
systematic review we evaluated which clinical subtypes of PD have been identified by CA, discuss 
their robustness and reflect on the methodological issues that may influence the results. 
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Methods
Search strategy
The following databases were searched on April 27th, 2009: PubMed (1949 to April 2009), EMBASE 
(OVID-version, 1980 to April 2009), and Web of Science (1945 to April 2009). The search consisted of 
the combination of the following terms: (1) Parkinson disease, and (2) heterogeneity, cluster analysis, 
K-means, self organizing maps, mixture models, data driven, or cluster combined with fuzzy, kernel 
based, or hierarchical. The search strategy was optimized for all consulted databases, taking into 
account the differences of database-specific technical variations. Additionally, the reference lists of 
all included articles were searched. The results were limited to articles in English, German, and Dutch. 
Methods of review
The selection procedure was performed by two independent reviewers (SR, JM). This assessment was 
not blind with respect to authors or institutions. The obtained articles were first screened by title, 
after which the abstracts of potentially relevant articles were reviewed. If the abstract was considered 
relevant, the full text of the article was studied. Studies were included if (1) the study population 
consisted of PD patients, (2) the existence of subtypes was evaluated by CA and (3) the CA was based 
on clinical characteristics. Studies that focused on a specific domain of the disease were excluded to 
avoid incomparable findings. 
Data extraction
Study methods and results were abstracted by one of the authors (SR). Whenever information 
was incomplete or unclear, the authors of that study were contacted with the request to provide 
additional information. Since the outcomes of CA are dependent on the applied method, the 
variables included in the analysis, the characteristics of the involved sample and the way data are 
processed,2,3 all information pertaining to these issues was collected and recorded on a standard 
score sheet. Specifics of these issues are detailed below.
Sample characteristics Characteristics of the included sample may affect the cluster structure. 
Therefore, it is important to know whether a sample represents a population of interest, e.g. de novo 
patients.4 Additionally, the sample size is of relevance for the generalizability of the findings, since 
small studies will yield less precise estimates.  
Variables selected for CA. It is important to select variables that are considered relevant in 
phenotyping and discriminating subtypes of the disease.4 
Data preprocessing. Variables are generally measured with different units of measurement. To 
adjust for differences due to scaling of the measurement instrument, the variables are usually 
standardized, for instance by transformation into Z-score or range. 
Clustering algorithm. CA can be performed by different techniques, of which hierarchical 
clustering and K-means clustering are the most common. K-means CA is a partitioning method, 
meaning that patients are assigned to a prespecified (K) number of clusters without a hierarchical 
structure. K initial clusters are formed, after which patients are assigned to the cluster they most 
resemble. Subsequently, cluster means are calculated after which the distance to each cluster mean 
is calculated for each patient. Patients are reassigned to another cluster if they are closer to that 
cluster mean than to the mean of the cluster they were allocated to in the previous step. In the next 
step cluster means are recalculated followed by calculation of the patients’ distances to the cluster 
means. This iterative process stops when no patients need to be reassigned, and the optimal solution 
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for the clusters is achieved.3
Local optimum. Cluster methods that involve iterative processes stop when an optimum is achieved. 
This optimum, however, may not be the optimal solution among all possible solutions but represent a 
so-called local optimum. The process of partitioning is sensitive to the starting points. To reduce the 
risk of ending in a local optimum, the clustering can be repeated a number of times with randomly 
chosen different starting points, after which the optimal solution is selected.5  
Determination of number of clusters. The validity of the cluster result is dependent on the 
estimation of the number of clusters.6 In K-means CA the number of clusters has to be indicated by 
the investigator. This optimal number can be estimated by statistical methods, of which the Calinski 
and Harabasz index (pseudo F-statistic)7 was considered most appropriate.8 It is important to report 
on which statistical grounds or other rationale the choice of the number of clusters was determined.
Cluster validation. Validation of the results is an important step since CA methods can always 
generate a division in clusters, which do not necessarily represent true subtypes.6 The results 
are preferably replicated in an independent sample. Other methods are cross-validation, the 
demonstration of stability, and face validity.2,4,9 
Interpretation of cluster results. The final goal of CA is to evaluate whether the cluster sizes 
and profiles are meaningful and clinically interpretable. A discriminant function analysis can be 
performed to evaluate which combination of variables best differentiates the subtypes. In contrast, 
F-values only provide insight in the magnitude of univariate differences between clusters. In post-hoc 
analyses, clusters can be further characterized on variables which were not included in the CA. This 
may provide insight in factors that play a role in the development of a specific phenotype profile.  
Results
The search strategy yielded 259 studies of which eight were judged eligible by at least one reviewer. 
The overall inter-reviewer agreement for the inclusion of the studies by reviewing titles and abstracts 
was 99.6% (Cohen’s Kappa 0.93). Differences were reconciled by consensus, after which eight studies 
were considered eligible for this review. Eight other studies performed CA in PD but focused on a 
specific domain of the disease and were therefore excluded.10-17 One eligible study was published 
as a congress abstract18 and as an article in a peer-reviewed journal.19 We included only the latter 
publication, resulting in seven included studies (Table 1). The selection process is presented in Figure 1. 
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PD: Parkinson’s Disease
CA: cluster analysis
*) Sum of studies excluded per criterion does not equal the total number of excluded studies, since 
some studies were excluded because of more than one exclusion criterion.  
Figure 1. Flow chart of study search and selection
Literature search conducted in
Medline 190 records
EMBASE 80 records
Web of Science 103 records
Total 373 records
 
After removal of duplicates
259 records
After screening by title
72 records
Studies excluded because of
- Population not (only) PD patients 21
- Subtypes not identified by CA 46
- No clinical variables in analysis 13
- CA study in PD patients, but
focused on specific clinical domain 8
Total number of studies excluded 64*
8 studies fulfilled the inclusion
criteria
7 studies included in qualitative
analysis
1 study excluded (18) since final results are
presented in Reijnders et al. 19
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Table 1. Methodology of cluster analyses on the spectrum of PD 
 







































































No. of patients  346  131  124  120  44  103  176  
Inclusion criteria, in 
addition to PD 









- age, yrs  











66.7 (10.4)  











64.4 (9.3)  
















63.2 (10.2)  
7.5 (6.4)  
NS
 
Data preprocessing  
 
Z-scores  Z-scores § No§ Z-scores § NS ‡ NS 
Clustering algorithm K-means K-means K-means K-means K-means ‡ K-means 
Basis of the 
determination of the 
number of clusters  
Non-
statistical †  









No criteria  
Cluster validation on 
independent sample  
Yes No No No  No No  No 
Evaluation of 
discriminative variables  







No  Yes, F -values  
Post hoc analysis of 
variables not included 
in CA 
Yes Yes Yes Yes Yes Yes Yes 
PD: Parkinson’s disease, H&Y; Hoehn and Yahr stage, yrs: years, SD: standard deviation, NS: Not 
Specified, CA: cluster analysis
§) Personal communication. *) Total sample is built op from two samples: N=224, age 73.2 (8.4), disease 
duration 9.5 (5.7), H&Y 2.8 (1.0); N=122, age 65.3 (10.0), disease duration 6.7 (5.0), H&Y 2.4 (0.8) (mean 
(SD)). ‡) Unknown. †) Based on changes in cluster distances in successive steps; face validity. **) Based 
on a clear distinction in clusters with a sufficiently large size. ††) Pseudo F-statistic, Cubic Clustering 
Criterion, squared correlation ratio. #) Aim to find two clusters.
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Table 2. Variables included in the cluster analyses
MF: motor fluctuations, dysk: dyskinesias, ADL: activities of daily living
Grey and black marked variables were included in the cluster analysis; the variables marked in black 
were discriminative variables that emerged from discriminant analysis or had large F-values. Details of 
measures and measurement instruments are provided in the Supplementary Appendix.
*) A cluster analysis was performed with all marked variables and with only the variables marked with 
*. Both analyses resulted in similar solutions (personal communication). 
Methodological  appraisal 
Study characteristics are presented in Table 1 and 2.
Sample characteristics All but one study analyzed >100 patients, with samples ranging from 4420 
to 17621 patients. All studies applied validated criteria to diagnose PD.22-24 Four studies applied 
additional inclusion criteria, which were based on disease duration in three20,25,26 and on disease 
severity in one study.27 One study did not provide patient characteristics for the total group.25 Only 
in the study of Post et al. age-at-onset was specified, which was 65.1(10.4) (mean (SD)).26 In the 
other studies, except that of Gasparoli et al.25, information on mean age-at-onset can be obtained 
by subtracting disease duration from age, but the SD is unknown. Mean age-at-onset was 55.721, 
56.627, 6220, 62.219, and 65.828 years. 





































Motor symptoms         
Onset symptom      
Cognitive impairment   *     
Depression         
Apathy        
Hallucinations        
Motor complications   *
*
     
Time to MF/dysk, 
years  
       
Time to falls, years         
Disease progression    *     
Disease severity         
Disease duration, 
years  
       
Age-at-onset, years    *      
Age, years    *      
Medication        
ADL        
*
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measures or measurement instruments for a similar clinical domain (Table 2 and Supporting Appendix). Six 
of the seven studies included motor symptoms assessed by the Unified Parkinson’s Disease Rating Scale 
(UPDRS), although different sum and subscores were used.19-21,25-27 Motor symptoms were combined with 
measures of cognition in five studies,19-21,26,27 of which four also included depression19,21,26,27 and age-at-
onset.19,21,26,27 Three of these latter four studies also included a measure of disease progression.19,26,27 Other 
variables were less frequently included (Table 2).
Data pre-processing. In five studies scores were standardized before analysis,19-21,26,27 which concerned 
transformation into Z-scores in three.19,26,27 One study presented results based on an analysis with 
unstandardized scores. However, repeating the analysis with scores transformed into Z-scores revealed 
similar findings (personal communication).28
Clustering algorithm. Information on the applied CA method was not reported in one study;25 all other 
studies used K-means CA.
Local optimum. None of the studies reported how they tried to avoid local optima.
Determination of number of clusters. One study determined the optimal number of clusters on 
statistical grounds by three different indices (Pseudo F-statistic, Cubic Clustering Criterion, squared 
correlation ratio).20 One study indicated that the aim was to find two clusters.25 Two studies evaluated 
two to five-cluster solutions after which the optimal number was determined based on changes in cluster 
distances in successive steps and face validity in one study19 and based on a clear distinction in clusters with 
a sufficiently large size in the other study.27 Two studies evaluated both two and three-cluster solutions and 
one a five-cluster solution without determining the optimal number of clusters.21,26,28
Cluster validation. Only the study of Reijnders et al.19 verified the cluster solution in a second sample; 
based on the cluster means and covariance matrices of the first sample they evaluated the probability of 
a cluster membership of patients in a second sample. That study, as well as two other studies,26,27 also 
evaluated post-hoc how variables that were not included in the CA differed between the clusters. Lewis 
et al.27 also evaluated to which extent patients consistently grouped together in the 3, 4, and 5 cluster 
solutions. Four studies did not report any information about validation of the cluster solution.20,21,25,28
Interpretation of  the results 
The studies identified five21, four19,27, three20,26, and two25,28 clusters. The sizes of all clusters were >5% of 
the total sample in all studies, except one in the study by Dujardin et al..20 In the latter study, however, 
this small cluster was discarded after the analysis because authors concluded that the patients in this 
cluster had developed Alzheimer’s disease (Table 3).
It is important to emphasize that all studies included a different set of variables in the CA (see Table 2). 
Since both the number and nature of included variables have a prominent role in the outcomes of the 
CA, all following results should be considered in the context the total set of variables that was included 
in the CA in each study. Consequently, the findings of different studies have limited comparability. 
Discriminative variables
Only one study performed a discriminant analysis to evaluate which variables best discriminated 
the subtypes.20 Three other studies presented F-values, indicating which variables showed large 
differences between clusters.21,26,28 It appeared that in two studies cognitive dysfunction, specifically 
executive dysfunction, best differentiated between clusters.20,21 In two other studies age-at-onset 
had large F-values,26,28 in combination with age and axial motor symptoms in one,26 and levodopa 
dose in the other study.28 As stated above, these discriminating variables should be considered in the 
context of the total set of variables, which varied betweens studies (see Table 2). 
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Cluster profiles
 The majority of studies reported two clusters with a largely similar profile regarding age-at-onset and 
rate of disease progression (Tables 3 and 4). 
The sizes of the clusters with the profile ‘Rapid disease progression and old age-at-onset’ differed 
considerably and ranged from 6% to 64% of the total sample. The mean age-at-onset ranged from 
61.021 to 72.926 years. Four studies found an association with axial impairment, either directly from 
the cluster profile19,26 or through post-hoc analyses.21,25 Three studies found an association between 
this profile and predominance of bradykinesia/rigidity (cluster profile 19; post hoc analysis21,25). 
Conflicting results for this cluster profile were found with respect to the association with motor 
complications (sporadic28 and frequent25) and cognitive impairment (unaffected27, mildly impaired19, 
and impaired21).
Clusters with the profile ‘Slow disease progression and young age-at-onset’ also differed in size 
ranging from 29%19 to 61%25 of the total sample. Mean age-at-onset ranged from 5027 to 59.128 
years. This cluster profile was further characterized in three studies by mild motor symptoms25-27 and 
absence of cognitive impairment.19,26,27 Conflicting results were reported on the association between 
this profile and the severity of motor complications (sporadic25 and severe19,27) and depressive 
symptoms (mild27 and severe28).
Lewis et al.27 and Reijnders et al.19 also distinguished a ‘bradykinesia/rigidity and PIGD-dominant’ and 
a ‘tremor-dominant’ profile. Notably, since these were the only studies that included the subdomains 
tremor, bradykinesia, and rigidity in the CA, this profile could not have been identified in other
studies.19,27 The first cluster profile showed similarities with the ‘rapid disease progression and old 
age-at-onset’ cluster profile whereas the latter was comparable to the ‘slow disease progression and 
young age-at-onset’ cluster profile. However, each profile had specific characteristics. 
Table 3. Identified cluster profiles and cluster sizes (% of total sample)
*) Sum of percentages does not equal 100, because one of the clusters was discarded.








































64  17  
 
 39  21  




29  34  36  41   61   
Intermediate onset, anxiety, depression
 
 27       
Tremor dominant 47    17     
Non-tremor dominant 17    26     
More severe motor & cognitive impairment      36   32  
Mild motor & mild cognitive impairment     59    
Motor only       47  
 100  100  100  100  95 * 100  100  
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of the cluster profile   
- motor impairment (total score) 21
- bradykinesia/ rigidity 19
- bradykinesia/ rigidity/tremor 26
- axial impairment19,26
 
- cognitive impairment 21
- mild cognitive impairment 19
- no cognitive impairment 27
- frequent motor complications 25
- sporadic motor complications 28
- mild motor symptoms 25-27
- no cognitive impairment 26-28
- severe depression 28
- mild depression 27
- severe motor complications 19
- sporadic motor complications 25
- high L-dopa dose 28
- modest motor symptoms 27
- no cognitive impairment 19,27
- no depression 19,27
- cognitive impairment 19,27
- executive dysfunction 27




not included in the CA
- predominance 
  bradykinesia/rigidity 21,25 
- axial impairment 21,25
- bilateral PD signs at onset 25
- frequent symptomatic 
  orthostasis 21
- low L-dopa dose 27,28
- short disease duration 19
- higher H&Y stage 26
- higher level of disability 26
- low level QoL (physical) 26
- predominance tremor 25
- absence of gait disturbance 25
- unilateral PD signs at onset 25
- severe motor complications 27
- large proportion using DA 27
- relatively long disease   
  duration 19
- younger age 19,28
- frequent tremor at onset 27
- anti-cholinergic medication 27
- relatively short disease 
  duration 19
- lower H&Y stage 19
- cognitive impairment 27
- relatively long disease 
  duration 19
- higher H&Y stage 19 
- worse ADL 19
- worse QoL (mobility,  
  cognition) 27
Table 4. Cluster characteristics and associations
CA: Cluster analysis, PD: Parkinson’s disease, L-dopa: levodopa, H&Y: Hoehn and Yahr, QoL: quality of life, 
DA: dopamine agonists, PIGD: postural instability and gait disorder, ADL: activities of daily living
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Discussion
We found seven studies that performed CA techniques on a combination of PD features with the aim to 
identify clinical subtypes in PD. The cluster profiles ‘old age-at-onset and rapid disease progression’ and 
‘young age-at-onset and slow disease progression’ emerged from the majority of studies.19,21,25-28 Two 
studies further distinguished a ‘tremor-dominant’ and a ‘bradykinesia/rigidity and PIGD dominant’ cluster 
profile.19,27 Other profiles were less consistently identified. These results suggest that age-at-onset and 
rate of disease progression are important determinants for subtypes in PD and are related to each other. 
Further, several studies found that the ‘old age-at-onset and rapid disease progression’ cluster profile was 
also characterized by axial motor symptoms, bradykinesia, and rigidity, whereas ‘young age-at-onset and 
slow disease progression’ was associated with mild motor and cognitive impairment. However, the results 
of the studies for either of these two profiles also clearly differed with respect to further characterization 
of the profiles and cluster sizes. 
Differences in design may at least partly account for the differences in cluster results between studies, 
since choices in the process of CA will affect the results. However, large variability between studies in 
characteristics of study populations, in variables included in the CA and in measurement instruments, 
and in the number of clusters in the solution rendered the comparison of the results between studies 
difficult. All these factors may have to some extent influence on the cluster result. As a consequence, it was 
impossible to indicate specific explanation for differences in, for instance, cluster profiles or prevalence. This 
was further complicated by incomplete reporting of methodological steps in most studies. Interestingly, 
studies that included a largely similar set of variables in the CA found four more or less similar profiles,19,27 
which indicates that these subtypes are rather robust considering the fact that they were consistently 
identified despite considerable differences in samples characteristics between studies. It may be expected 
that application of CA in a more standardized design will increase the yield of studies on subtypes. 
The study populations showed differences in age, disease duration and severity. Information on age-at-
onset and the distribution of this characteristic, which was found to be an important determinant for 
the cluster profiles, was lacking in the majority of studies, rendering results difficult to interpret and to 
compare between studies. 
Additionally, we identified several issues regarding the selection of variables that were included in the 
CA to identify PD subtypes. First, large differences between studies were noted in the extent to which 
clinical domains of PD were included in the analysis. It is possible that domains essential in discriminating 
subtypes may have been missed. This also holds for subdomains with independent behavior with respect 
to associations with other variables. Second, all but two studies20,25 included not only clinical impairments, 
but also variables like age-at-onset or medication. The use of mixtures of clinical and nonclinical variables in 
establishing distinct phenotypes is questionable and may yield phenotype profiles that are conceptually less 
meaningful. Third, since PD is a progressive disorder, the phenotypic expression of patients may change 
with increasing disease duration. Only the studies of Gasparoli et al.25 and Dujardin et al.20 included patients 
with similar disease duration; all other studies included patients with variable disease durations and thus 
ran the risk of identifying subtypes that reflect different stages of the disease rather than reflecting different 
phenotypic subtypes. It should be noted that all studies included in this review had a cross-sectional design 
which ruled out the possibility of detecting subtypes with different longitudinal patterns of change, that 
is, different disease courses. Longitudinal studies could provide important information, in addition to the 
phenotypic profiles that are identified by cross-sectional studies. 
K-means, the CA technique applied by at least six of the seven included studies, does not indicate how many 
clusters are optimal, which is unfortunate since the number of clusters in the solution has consequences for 
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the cluster profiles and sizes. Only one study dealt with this problem by calculating indices to determine the 
optimal number of clusters.20 A second limitation of this clustering technique is that K-means is sensitive 
to outliers. In that respect, it is irrational that one study discarded one of the clusters after the analysis, 
since the excluded patients possibly had deviant scores and thus could have distorted the results.20 Third, 
K-means is an iterative clustering method and thus studies ran the risk of ending in a local optimum. 
However, none of the studies reported that they attempted to avoid local optima. 
Another important observation is that only one study validated the outcomes in a second sample, an 
essential step to obtain insight in the robustness and generalizability of the findings.19  
In spite of these methodological limitations and variations rendering comparisons difficult, the advantages 
of studying subtypes in an objective manner were also noted. When compared to studies on clinical 
subtypes based on prespecified criteria as described in the review of Foltynie et al.2 two important 
differences between the studies of interest in both reviews were noticed. First, the subtypes as described in 
the study by Foltynie et al.2 were classified by only one dimension, i.e., one variable, whereas in the studies 
included in this review subtypes were classified and characterized on the basis of different dimensions. 
Additionally, four studies included in the present review allowed insight in the extent to which each variable 
contributed to the classification of the subtypes.20,21,26,28 Second, in the studies reported in the review by 
Foltynie et al.2 young age-at-onset, for example, was defined as < 40 years, while the mean age-at-onset 
of the young onset subtypes that were found in the studies included in the present review ranged from 50 
to 60 years and already showed clear differences with profiles with an old age-at-onset. Thus researcher-
based cut-off criteria may differ from mean values of clusters that are determined by CA and this may have 
consequences for the subtypes. 
In conclusion, although CA has a great potential in identifying subtypes, the current review shows that 
the findings of different CA studies in PD are difficult to compare because of methodological differences 
between studies. These differences combined with methodological limitations in many of the studies lead 
to not fully conclusive results. In spite of the methodological differences, a profile characterized by higher 
age-at-onset and faster rate of disease progression and a profile characterized by lower age-at-onset 
and slower rate of disease progression, emerged from most studies. Since the identification of subtypes 
potentially has consequences for studies on the etiology of PD as well as for patient care, there is a need 
for CA studies with a rigorous design using a standardized approach. Future studies are recommended 
to 1) select a sample of PD patients with a preferably similar disease duration; 2) critically select a set of 
conceptually similar clinical variables that adequately represent the clinical spectrum of PD and are relevant 
in discriminating phenotypic profiles; 3) take the limitations of K-means into account or apply another CA 
technique that does not have these limitations; 4) critically evaluate the cluster results: Are they clinically 
meaningful and interpretable? Which variables discriminate best between clusters? How do the clusters 
differ with respect to variables that were not included in the CA?; 5) validate the results in independent 
samples. Studies that apply a similar design in different cohorts and take into account the abovementioned 
recommendations will likely increase our knowledge on subtypes in PD. 
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Motor symptoms
Reijnders1: Separate scores for tremor, hypokinesia-rigidity, and PIGD: Unified Parkinson’s Disease 
Rating Scale (UPDRS) III items 16, 20, 21; 20,31; 13-15, 29, 30.2
Post3: Levodopa responsive symptoms (facial expression, tremor, rigidity, bradykinesia): sum of 
UPDRS III item 19-26, 31; levodopa non-responsive symptoms (speech, axial impairment): sum of 
UPDRS III item 18, 27-30.2
Lewis4: Tremor ratio score: UPDRS III items 5,7,12-15,18,19,27-44 divided by 16, 20-26.2
Dujardin,5 Gasparoli,6 Graham7: UPDRS III total score.2
Graham7: Alternate finger tapping test (left right separate scores); UPDRS III subscores for left and 
right.2
Cognitive impairment
Reijnders,1 Post,3 Schrag,8 Lewis4: Mini-Mental State Examination (MMSE).9
Lewis4: National adult reading test,10 Pattern recognition memory,11 Tower of London planning test.12
Dujardin5: Mattis Dementia Rating Scale,13 Grober and Buschke test,14 Stroop word-colour test, 
semantic task, alternating task.15
Graham7: Blessed Dementia Scale Information-Memory-Concentration test,16 CANTAB subtests: 
Spatial Recognition Memory,11 Spatial Working Memory,17 Digit Ordering Paradigm,18 Attentional Set 
Shifting,19 Letter Fluency Assessment.20
Depressive symptoms
Reijnders1: Montgomery-Åsberg Depression Rating Scale.21
Post3: Hospital Anxiety and Depression Scale.22
Schrag,8 Lewis4: Beck Depression Inventory.23
Apathy
Reijnders1: UPDRS I, item 4.2 
Hallucinations
Reijnders1: UPDRS I, item 2.2
Schrag8: Presence of hallucinations.
Motor complications 
Reijnders1: UPDRS IV.2
Schrag8: Presence of motor fluctuations/ dyskinesias.
Gasparoli6: Measure is not presented in the study.
Disease progression
Reijnders,1 Lewis4: UPDRS I-III divided by disease duration.2
Post3: UPDRS III divided by disease duration.2
Schrag8: Hoehn and Yahr stage divided by disease duration.24
Supporting Appendix:  Measures and measurement instruments of 
variables selected for cluster analysis
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Disease severity
Schrag8: Hoehn and Yahr scale.24
Medication
Schrag8: Levodopa dose.
Lewis4: 3 categories: 1) no levodopa; 2) <1000 mg levodopa, with or without concomitant dopamine 
agonists or dopamine agonists monotherapy; 3) >1000 mg levodopa with or without concomitant 
dopamine agonists.
Activities of daily living
Graham7: UPDRS II.2
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Abstract
Objective: Insight in how impairments and disabilities related to Parkinson’s disease (PD) 
influence health related quality of life (HRQoL) is required to review adequacy of current management 
strategies. 
Methods: The Scales for Outcomes in Parkinson’s disease (SCOPA) evaluation was used to assess 
impairments and disabilities. HRQoL was assessed with the EuroQol-5D Visual Analogue Scale. 378 
patients with PD who participated in the SCOPA/PROPARK cohort were assessed while on their 
usual treatment. Multiple linear regression analysis and structural equation modelling were used to 
construct a model of factors that influence HRQoL. 
Results: A model with good fit was constructed that identified various impairments and 
disabilities as important contributors to HRQoL in PD. Of the disabilities, psychosocial well-being had 
a larger impact on HRQoL than physical functioning. Of the impairments, depression had the largest 
contribution to HRQoL, followed by axial motor symptoms, gastrointestinal symptoms, and urinary 
symptoms. In addition, pain, psychiatric and motor complications, and daytime sleepiness had small 
but significant influences on HRQoL. 
Conclusions: Multiple factors, including disabilities, nonmotor symptoms and axial motor 
symptoms, affect HRQoL in patients with PD. In patients who are on symptomatic treatment 
aiming to alleviate mainly motor symptoms, there is a large impact on HRQoL of nonmotor and 
nondopaminergic symptoms. Research is warranted to develop and evaluate management strategies 
for the aspects that currently impact on HRQoL as psychosocial well-being, depressive symptoms, 
axial motor symptoms, gastrointestinal symptoms, and urinary symptoms. These findings call for a 
multidisciplinary approach in the care of these features. 
Introduction
Parkinson’s disease (PD) is generally known as a movement disorder in which dopamine replacement 
therapy may alleviate some of the motor symptoms early in the disease but eventually fails with the 
progression of the disease. However, there is now an increasing awareness that the clinical spectrum is 
much broader, encompassing also many nonmotor features including depression, autonomic dysfunction, 
cognitive dysfunction, night-time sleep problems and daytime sleepiness.1 Additionally, dopaminergic 
treatment may induce both motor and psychiatric complications. Together, the debilitating effects of 
PD and its therapy have a considerable impact on health, physical and psychosocial well-being, and are 
associated with a decrease in health-related quality of life (HRQoL). HRQoL is defined as those aspects 
of self-perceived well-being that are related to or affected by the presence of disease or its treatment.2 
Numerous factors impact on HRQoL in PD, including disease severity, disease duration, postural instability 
and falls, motor complications, depression, anxiety, pain, sleep, cognitive impairment, hallucinations and 
problems with activities of daily life (ADL).3-5 However, for some of these factors, like motor complications, 
studies have yielded inconsistent findings.6,7  Furthermore, many studies have explored relations between 
one or two domains and HRQoL without taking into account the broadness of the clinical spectrum of 
PD or the complex interplay of domains that make up the pathway that links impairments to disability 
to HRQoL. The Scales for Outcomes in Parkinson’s disease (SCOPA) model is a comprehensive evaluation 
of PD that is based on the disablement process: a pathway linking impairments, disability and global 
outcomes of health.8 Using the SCOPA evaluation, we aimed to identify which impairments and disabilities 
contribute to HRQoL and to construct a model based on these disease-specific determinants in PD.
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Methods
Study design 
The study is part of the “PROfiling PARKinson’s disease” (PROPARK) study, a longitudinal cohort study 
of patients with PD, who are profiled on phenotype, genotype, disability, and global outcomes of 
health. Valid and reliable measurement instruments for the different domains of PD were derived 
from the SCOPA project. (www.scopa-propark.eu) Data obtained from the first annual evaluation of 
420 patients who were included in the period from May 2003 to March 2006 was used for analysis.
 
Participants
All patients fulfilled the United Kingdom Parkinson’s Disease Society Brain Bank criteria for idiopathic 
PD.9 Age-at-onset and disease duration are important determinants of disease course in PD and are related 
to various manifestations of the disease.10,11 To obtain an adequate distribution of these characteristics 
across the cohort, we constructed four strata, based on age-at-onset (onset of the first symptoms as 
perceived by the patient (</ > 50 years)) and disease duration (< / > 10 years). Recruitment stopped if 
approximately 100 patients per stratum were included. The principal centre (Leiden University Medical 
Centre (LUMC) recruited 186 patients (44%), other university hospitals recruited 54 patients (13%) 
and regional hospitals recruited 180 patients (43 %). No other selection criteria were applied. The 
study was approved by the medical ethical committee of the LUMC and all participants gave informed 
consent.
Outcome measures
Information was obtained on clinical and sociodemographic variables and included age-at-onset, 
disease duration, disease severity measured with the Hoehn and Yahr scale (H&Y),12 medication, falls 
in the last year, age, marital stage, educational level, and employment status. Levodopa equivalent 
(LDE) units were calculated according to the formula described by Esselink.13
The following domains were assessed:
Impairments: Motor symptoms and motor complications (SPES/SCOPA, sections motor symptoms 
(MS) and motor complications (MC)),14 cognitive dysfunction (SCOPA-COG)15 and Mini Mental 
State Examination (MMSE),16 psychiatric complications (SCOPA-PC),17 depressive symptoms (Beck 
Depression Inventory (BDI)),18 night-time sleep problems (NS) and daytime sleepiness (DS) (SCOPA-
SLEEP sections NS and DS) ,19 autonomic dysfunction (SCOPA-AUT),20 and pain (Visual Analogue 
Scale (VAS) for pain). Patients were asked to rate their average pain in the last month on a line 
ranging from 0 (no pain) to 100 (worst imaginable pain).
Disability: Activities of Daily Living (SPES/SCOPA-ADL)14 and psychosocial wellbeing (SCOPA-PS).21 
Quality of Life: HRQoL was measured using the VAS from the EuroQoL (EQ-5D), a generic HRQoL 
instrument.22 Patients were asked to rate their current health status on a line ranging from 0 (death) 
to 100 (best imaginable health state). 
Except for the SCOPA-COG and the EQ-VAS, higher scores reflect more problems. 
Data were collected by means of self-report questionnaires (SCOPA-SLEEP NS and DS, SCOPA-AUT, BDI, 
SCOPA-PS, EQ-VAS, VAS-PAIN), which patients completed at home two weeks before their assessment. 
Furthermore, a trained researcher assessed the SPES/SCOPA sections MS, MC, and ADL, SCOPA-COG, and 
the modified PPRS. A partner, relative, or caregiver was requested to be present during the examination. 
The majority of the patients were assessed at the LUMC. To avoid bias towards recruiting less severely 
affected patients, patients who were unable to come to the hospital were assessed at home. 
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Statistical analysis
If patients had 25% or more missing data on one of the impairment or disability domains, they were 
excluded from the analysis. If patients had less then 25% missing data on a scale, the missing data 
were imputed by the mean values of the non-missing items. Means and standard deviations for all 
impairment and disability domains and HRQoL were calculated. Pearson correlations were calculated 
between all impairment and disability domains and HRQoL. 
Path analysis was used to test the linkages among model variables.23
Estimating path coefficients: Using SPSS 14.0, path coefficients were estimated using multiple 
linear regressions for the following dependent variable in the model: the (1) SPES/SCOPA-ADL and 
(2) SCOPA-PS as dependent variable and all impairment domains as independent, and (3) the EQ-VAS 
as dependent variable and all impairment and disability domains as independent variables. Non-
significant path coefficients were excluded from the model. 
Multiple linear regressions were also performed using subdomain scores instead of the total score for 
domains that significantly contributed to the model, in order to get more insight in their contribution. 
The SPES/SCOPA-MS was divided into the subdomains “bradykinesia-rigidity” (items 3a,b + 4a,b), 
“tremor” (items 1a,b + 2a,b), and “axial symptoms” (items 5,6,7,8,9,10). The SPES/SCOPA-MC was 
divided into dyskinesias” (items 18 + 19) and “motor fluctuations” (items 20 + 21). The SCOPA-
AUT consists of the subdomains “Gastro-intestinal” (GI), “Urinary” (UR), “Thermoregulatory” (TR), 
“Cardiovascular” (CV), Pupillomotor” (PM), and “Sexual Dysfunction” (SX). 
Model fitting: The overall fit of the final model was assessed using the structural equation modelling 
program EQS 6.1 for Windows.24 Multiple indices can be calculated that show how well the data 
fit the model. The chi-square test for goodness-of-fit should be nonsignificant (indicating that the 
model does not differ from the data) but is sensitive to sample size. Five other goodness-of-fit indices 
were evaluated. The Bentler-Bonnet normed fit index (NFI), the nonnormed fit index (NNFI), and the 
comparative fit index (CFI) range between 0 and 1, whereby 0.90 is the minimally acceptable value, 
with 0.95 being the minimum if the chi-square test is significant. The root means square error of 
approximation (RMSEA) estimates the lack of fit in a model compared to a perfect model; above 0.1 
indicates a poor fit, under 0.08 indicates a reasonable fit, and under 0.05 indicates a good fit.25 The 
standardized root mean square residual (SRMR) indicates good fit if the value is less than 0.08.26 
Results
Patients
Forty-two patients (10%) had more then 25% missing data in one of the scales and were excluded 
from the analysis. Complete data was obtained from 378 PD patients (66% men). The mean (SD) 
age was 60.0 (11.2) years and the mean (SD) disease duration was 10.2 (6.4) years (Table 1). Patients 
who were excluded from the analysis because of missing data were significantly older, had longer 
disease duration, a higher H&Y stage, and were more often female. Furthermore, these patients had 
a significant lower HRQoL (worse) and scored higher (worse) on all other domains. 
The mean scores of the impairment and disability domains and HRQoL are presented in Table 2.
Correlations and multiple linear regression
The SPES/SCOPA-ADL had high correlations with the SPES/SCOPA-MS (r=0.67) and the SCOPA-AUT 
(r=0.54) (Table 3). The SCOPA-PS had the highest correlations with the BDI (r=0.69) and the SCOPA-
Opmaak 2.indd   38 21-09-12   15:32
Chapter 3  |  39
AUT (r=0.57), whereas the EQ-VAS for HRQoL had the highest correlations with the SCOPA-PS 
(r=-0.59) and the BDI (r=-0.56).
Table 1. Patient characteristics
N 378
men/women (%man) 250/128 (66.1%)
Age, yrs (SD) 60.0 (11.2)
Years of education (SD) 12.1 (4.1)
Patient with partner (%) 310 (82.0 %)
Employment status: employed
                           not employed
103 (27.2%)
275 (72.8%)
Disease duration, yrs (SD) 10.2 (6.4)
Age onset, yrs (SD) 49.8 (11.8)
H&Y stages 1 / 2/ 3/ 4/ 5 / missing 15 / 190 /105 / 59 / 4 / 3
MMSE (SD) (N< 24, %) 27.0 (2.5) (35, 9.3 %)
Falls in last year (SD) 1.3 (61.5)
Patients on levodopa, N (%) 246 (65%)
Patients on dopamine agonist, N (%) 266 (70%)
Levodopa equivalent units (mg) 591.9 (460.9)
Family history of PD (%) 98 (25.9%)
H&Y, Hoehn and Yahr ; MMSE, Mini Mental State Examination
Table 2. Outcome measures
Domain Outcome measure (scale range) Mean (SD)
Motor symptoms SPES/SCOPA-MS (0-42) 13.1 (4.6)
Motor complications SPES/SCOPA-MC (0-12) 1.6 (2.4)
Cognitive dysfunction SCOPA-COG (0-43) 26.2 (5.9)
Depressive symptoms BDI (0-63) 9.8 (6.3)
Autonomic dysfunction SCOPA-AUT (0-69) 17.5 (8.4)
Psychiatric Complications Modified PPRS (0-18) 2.0 (1.9)
Night-time sleep problems SCOPA-SLEEP NS (0-15) 4.4 (3.7)
Daytime sleepiness SCOPA-SLEEP DS (0-18) 4.7 (3.7)
Pain VAS-PAIN (0-100) 28.8 (25.2)
ADL SPES/SCOPA-ADL (0-21) 8.6 (3.3)
Psychosocial function SCOPA-PS (0-33) 8.4 (4.9)
Health related Quality of Life EQ-VAS (0-100) 67.8 (14.2)
SPES/SCOPA-MC: SPES/SCOPA motor complications; BDI: Beck Depression Inventory; Modified PPRS: 
Modified Parkinson Psychosis Rating Scale; SCOPA-SLEEP NS: SCOPA-SLEEP Night-time sleep; SCOPA-
SLEEP DS: SCOPA-SLEEP Daytime sleepiness; SPES/SCOPA-ADL: SPES/SCOPA Activities of Daily Living; 
SCOPA-PS: SCOPA-Psychosocial functioning; EQ-VAS: EuroQol-Visual Analogue Scale
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Table 3. Pearson correlation matrix of impairment and disability domains and health related 
quality of life
EQ-VAS SPES/SCOPA-ADL SCOPA-PS
SPES/SCOPA-MS -0.331 0.671 0.421
SPES/SCOPA-MC -0.281 0.371 0.261
SCOPA-COG 0.241 -0.271 -0.201
BDI -0.561 0.311 0.691
SCOPA-AUT -0.401 0.541 0.571
SCOPA-PC -0.311 0.381 0.421
SCOPA-SLEEP NS -0.331 0.162 0.381
SCOPA-SLEEP DS -0.191 0.321 0.281
VAS-PAIN -0.281 0.181 0.181
SPES/SCOPA-ADL -0.421 - 0.511
SCOPA-PS -0.591 0.511 -
SPES/SCOPA-MC: SPES/SCOPA motor complications; BDI: Beck Depression Inventory; Modified PPRS: 
Modified Parkinson Psychosis Rating Scale; SCOPA-SLEEP NS: SCOPA-SLEEP Night-time sleep; SCOPA-
SLEEP DS: SCOPA-SLEEP Daytime sleepiness; SPES/SCOPA-ADL: SPES/SCOPA Activities of Daily Living; 
SCOPA-PS: SCOPA-Psychosocial functioning; EQ-VAS: EuroQol-Visual Analogue Scale
1correlation is significant at the 0.001 level
2correlation is significant at the 0.01 level
3correlation is significant at the 0.05 level
The impairment domains motor symptoms, motor complications, autonomic dysfunctions, and 
daytime sleepiness explained 57% of the variance in the ADL domain. The impairment domains 
depressive symptoms, psychiatric complications, motor symptoms, and autonomic dysfunction 
explained 58% of the variance in the PS domain. The disability domains ADL and PS and the 
impairment domains pain and depressive symptoms together explained 43% of the variance in the 
HRQoL. Two impairment domains that did not significantly contribute to this model were cognitive 
dysfunction and night-time sleep problems. 
The group of patients that was excluded because of missing values had significant lower SCOPA-
COG scores (26.2 (5.9) versus 20.8 (7.2) p=0.000) and higher SCOPA-SLEEP NS scores (4.4 (3.7) 
versus 6.0 (4.0) p=0.010). However, the correlation between SCOPA-COG and EQ-VAS were the 
same in both groups, r=0.24, whereas the correlation between the SCOPA-SLEEP NS and EQ-VAS was 
lower for the group that was excluded (r=-0.33 versus r =-0.08).
Model evaluation
The overall fit of the final model that encompassed only the significant paths was assessed using 
EQS. The chi-square test was significant, which was expected given the large sample size. The other 
fit indices, however, fulfilled the cut-off criteria of a good model fit (Table 4). Except for depressive 
symptoms and pain, which have a direct influence on HRQoL, most impairment domains have an 
indirect relation through the disability level (Figure 1). 
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Table 4. Summary of final model fit statistics





RMSEA (90% CI) 0.059 (0.030-0.088)
2, model chi-square value; df, model degrees of freedom; NFI, Bentler-Bonett normed fit index; NNFI, 
Bentler-Bonett non-normed fit index; CFI, Bentler’s comparative fit index; SRMR, standardized root 
mean square residual; RMSEA, root mean square error of approximation; CI, confidence interval 
around RMSEA.
Depressive symptoms had the largest contribution to HRQoL, which was established through a direct 
relation with HRQoL and an indirect relation via the PS domain. Motor symptoms and autonomic 
dysfunction had indirect relations with HRQoL through both the PS and ADL domains. The indirect 
relation from psychiatric complications occurred through the PS domain, whereas the indirect relation 
of daytime sleepiness and motor complications occurred through the ADL domain.


































All path coefficients are statistically significant at P =0.05. Covariances between impairment domains 
are not shown for reason of readability.
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Model evaluation with subdomains
“Axial symptoms” was the only motor subdomain that contributed significantly to the PS domain 
and explained 31% of the variance. All three motor subdomains contributed significantly to the ADL 
domain explaining 60% of the variance, in which axial symptoms had the largest contribution and 
tremor the smallest contribution. Both motor fluctuations and dyskinesias contributed significantly to 
the ADL domain, explaining 14% of the variance. Only the subdomains GI, UR and PM of autonomic 
dysfunction contributed significantly to the ADL domain, and explained 32% of the variance. The 
subdomains GI, TR, UR, and CV contributed significantly to the PS domain, explaining 33% of the 
variance in the PS domain. The GI and UR subdomains were the most important contributors to both 
the PS and ADL domain. 
Model evaluation in subgroups
To evaluate the influence of disease duration in the model, the path analysis was performed in two 
subgroups based on disease duration (disease duration shorter (N=205) or longer (N=173) than 10 
years) (Table 5).
Table 5. Significant domains in path analysis in PD subgroups.
Disease duration   























R2 = 0.44 R2 = 0.40
PS: Psychosocial functioning 
ADL: Activities of Daily Living 
HRQoL: Health related quality of life
The models that emerged for each group were very similar, except for the pain and ADL, which lost 
their significant direct relation to HRQoL in patients with a disease duration longer than 10 years. 
Compared to the model that was based on all patients, the models for both disease duration groups 
lost the contribution of psychiatric complications to PS and DS to ADL.
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Discussion
HRQoL represents the overall experienced impact of the disease and its consequences on a person’s 
wellbeing. Some diseases are expressed in one impairment domain, and their impact on disability 
and HRQoL is generally straightforward. PD, however, is characterized by a broad spectrum of 
primary disease-related motor and nonmotor manifestations. On top of these primary PD-related 
impairments, medical interventions may induce motor or psychiatric complications or DS. The 
impact of PD on patients’ HRQoL is thus determined by the complex interaction of the motor and 
nonmotor symptoms of the disease, the consequences of therapy and the functional consequences 
of the disease. This study shows that HRQoL in PD can be described by a good fitting model that 
disentangles the contributions of components in the pathway that links impairments and disabilities 
to HRQoL. Interestingly, on the disability level, the influence of the PS domain on HRQoL was larger 
than that of the ADL domain, underscoring the importance of psychosocial functioning in HRQoL of 
patients with PD.  
Most impairments exerted an indirect influence on HRQoL through one or both of the disability 
domains. Pain was the only impairment domain with only a direct influence on HRQoL and its 
impact on HRQoL has been reported earlier.5 In line with other studies,27-29 our study highlights that 
depressive symptoms had the largest contribution to HRQoL, which was portrayed in our model by 
a direct influence on HrQoL as well as an indirect influence through the PS domain. As depressive 
symptoms have now been highlighted repeatedly as the main contributor to HRQoL in PD, it remains 
surprising that in both patient management and trials, depression is insufficiently prioritized. Both 
daytime sleepiness and motor complications were only related to ADL whereas autonomic dysfunction 
contributed to both physical (ADL) and psychosocial (PS) functioning. Within the autonomic domain, 
gastrointestinal and urinary symptoms had the largest influence on HRQoL. Within the motor 
complications, both motor fluctuations and dyskinesias were significant contributors to HRQoL.
Motor symptoms had only indirect relations with HRQoL through both disability domains, and its total 
contribution to HRQoL was less than that of depression. Of motor symptoms, axial symptoms had the 
largest influence on both psychosocial and physical functioning. Motor symptoms and ADL, which till 
recently dominated the content of assessment scales in PD, were not the main contributors to HRQoL 
in patients with PD. However, it is important to keep in mind that dopaminergic replacement therapy 
aiming to alleviate part of the motor symptoms is the mainstay treatment of PD. It can be assumed 
that the contributions to the total model on HRQoL in PD would have been different, if this treatment 
had not been available. The impact of dopaminergic therapy on the model is further underscored 
by our finding that “axial symptoms”, which are mainly of nondopaminergic origin, had the largest 
influence on both the PS and ADL domain. 
Neither cognition nor night-time sleep, contributed to HRQoL. Consistent with former studies,30,31 the 
univariate correlations between HRQoL and night-time sleep problems (r=-0.33), and between HRQoL 
and cognitive dysfunction (r=0.24) were significant, but their influence disappeared in the final model. 
It is likely that the strong association between night-time sleep problems and depressive symptoms 
(r= 0.49) resulted in the exclusion of night-time sleep problems from the model.32 The finding that 
cognition does not play a role in HRQoL is surprising, but robust, as two other studies have revealed 
similar results in multiple linear regression analysis.33,34 Contrary to night-time sleep problems, cognitive 
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dysfunction was in this study not strongly correlated to other domains of PD (all r < 0.40) and therefore 
the question remains how this finding can be explained. One explanation could be that cognitive 
decline played little role in this cohort, or that patients with cognitive impairment had missing values 
and where therefore not included in these analysis. Although the patients that were excluded had 
indeed more cognitive problems, they had also a worse HRQoL and the correlation between cognition 
and HRQoL was the same in both groups. Another explanation could be that the cognitive assessment 
describes the current cognitive status and this does not automatically reflect cognitive decline since 
the premorbid variance of normal cognition is large. For most other domains, like motor symptoms 
or psychiatric complications, a score of zero is expected before the onset of PD and a higher score 
therefore implies more severe problems. A longitudinal study that assesses the influence of change in 
cognition in relation to change in HRQoL is necessary to get more insight in this issue. 
The HRQoL model that was constructed appears robust, as it largely remained the same when 
evaluated in subgroups with a short and long disease duration. Depressive symptoms, psychosocial 
well-being, and autonomic dysfunction apparently remain important contributors to HRQoL along 
the course of the disease. The most prominent difference between the models of the two subgroups 
is the lack of a significant contribution of ADL to HRQoL in patients with long disease duration.  
A limitation of the study was the selective exclusion of patients with too many missing values. In 
addition, the stratification of the cohort based on age-at-onset and disease duration and the high 
recruitment of patients from academic hospitals (57%) may make the group less representative of 
the PD community.  However, the remaining group of patients was still large and reflected the full 
spectrum of PD, with mean disease duration of 10 years and disease stages ranging from H&Y stage 
1 to 5. The model incorporates only disease-specific aspects that explain 43 % of the variance in 
HRQoL. This implies that other aspects not incorporated in the model play a role as well. Educational 
level, mastery, or psychological adjustment have indeed been described to impact on HRQoL in 
PD.33,35,36 Incorporating more variables in the model would on the one hand increase the amount of 
explained variance but conversely decrease the comprehensibility of the model. The main objective 
of this study was to evaluate the contribution of disease-specific factors to HRQoL, so as to highlight 
issues that require further attention in the management of patients with PD. Indeed, multiple factors 
affect HRQoL in patients with PD on symptomatic treatment. Research is warranted to develop and 
evaluate management strategies for the aspects that currently impact on HRQoL as psychosocial 
well-being, depressive symptoms, axial motor symptoms, gastrointestinal symptoms, and urinary 
symptoms. These findings call for a multidisciplinary approach in the care of these features.
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Abstract
Objective: To identify patterns of motor disturbances in Parkinson’s disease (PD) and evaluate 
their relation with other PD domains.
Methods: A cohort of 399 PD patients was randomly divided into two samples. Factors within the 
motor section of the SPES/SCOPA were identified by exploratory factor analysis on data from the first 
sample and next tested by confirmatory factor analysis in the second sample. Relations with other PD 
domains were evaluated by regression analyses.
Results: A four factor model was found to be valid. This included a tremor, a bradykinetic-
rigid, and two axial factors. One axial factor (’rise’, ‘gait’, ‘postural instability’) was associated with 
age and cognition, while the other axial  factor (‘freezing’, ‘speech’, ‘swallowing’) was related to 
dopaminergic medication and complications of therapy. Both other factors showed no relevant 
associations with demographic and clinical characteristics. 
Conclusions: The identification of motor factors and their relation with other domains of the 
disease may help to elucidate the mechanisms responsible for these associations and provide an 
objective base for further research on subtypes in PD.
Introduction
In Parkinson’s disease (PD) is considerable heterogeneity in the expression of clinical manifestations 
and progression of the disease, suggesting the existence of subtypes. Several motor subtypes of the 
disease have been suggested, mostly based on clinical observations: a tremor dominant subtype, 
associated with mild disease progression1-3; an akinetic-rigid subtype, associated with more severe 
cognitive impairment and depressive symptoms than patients with tremor4,5; a subtype in which 
postural instability and gait dysfunction (PIGD) are most prominent, associated with cognitive 
impairment and a more progressive disease course.1,3,6,7
When studying subtypes through a more data-driven approach, studies have analyzed the motor 
domain in various ways such as a total score,8 as a ratio of tremor and non-tremor items,9 and as 
subscores of tremor, hypokinesia/rigidity, PIGD.10 An objective determination of groups of variables 
that group together as manifestations of an underlying construct may provide a stronger basis for 
classification into subtypes and enhance our understanding of the underlying pathophysiology. 
Exploratory factor analysis (EFA) is a method that can be used in this respect; it identifies groups of 
closely related variables (‘factors’) among a larger set of variables.11 Several studies applied EFA on 
the items of the motor section of the Unified Parkinson’s Disease Rating Scale (UPDRS)12-15 and the 
Short Parkinson’s Evaluation Scale (SPES).12 These studies yielded inconsistent results, likely because 
of differences in scale content and size and composition of samples. Confirmatory factor analysis 
(CFA) is a method to test hypotheses on constructs that underlie a set of variables and is more 
powerful than EFA. Only one study performed CFA on the motor items of the UPDRS, which resulted 
in five main factors (rigidity; tremor; bradykinesia; axial impairment; speech/hypomimia), as well as 
two separate factors reflecting laterality.16 
As the first step in a data-driven determination of subtypes, this study aimed to identify patterns of 
motor impairments in PD by both exploratory and confirmatory factor analysis. Secondly, the relation 
between motor factors and nonmotor impairments of PD were evaluated.
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Methods
 The study is part of the “PROfiling PARKinson’s disease” (PROPARK) study, a longitudinal cohort 
study of patients with PD, who are profiled on phenotype, genotype, disability, and global outcomes 
of health using valid and reliable assessment instruments for PD (www.scopa-propark.eu). Findings 
obtained from the first annual evaluation of 417 patients, assessed between May 2003 and March 
2006, were used for analysis. The study was approved by the medical ethical committee of the Leiden 
University Medical Centre and all patients gave informed consent.
All patients fulfilled the United Kingdom Parkinson’s Disease Society Brain Bank criteria for idiopathic 
PD, with the exception that positive family history was not regarded as an exclusion criterion.17 
Patients who underwent stereotactic surgery were excluded from analysis. The recruitment procedure 
has been described elsewhere.18
To assess the motor impairments of patients, the motor section of the SPES/SCOPA rating scale 
was used.19 This scale has a good balance between items reflecting motor features of early and 
late stage disease, and has good metric properties.19 The SPES/SCOPA-motor consists of 10 items 
with response options ranging from 0 to 3, where higher scores reflect poorer motor function. For the 
current study, data obtained for cognition (SCOPA-COG),20 autonomic symptoms (SCOPA-AUT),21 
depressive symptoms (Beck Depression Inventory (BDI)),22 psychotic symptoms (SCOPA-Psychiatric 
Complications (SCOPA-PC),  items 1-5),23 nighttime sleep problems and excessive daytime sleepiness 
(SCOPA-SLEEP),24 and motor complications (SPES/SCOPA-Motor Complications)19 were used for post-
hoc analyses. In all scales higher scores also reflect more severe symptoms, except for the SCOPA-COG. 
For reasons of comparability, these scores were inversed. Instruments were either self-completed (SCOPA-
AUT, BDI, SCOPA-SLEEP) or administered by trained research associates (SCOPA-COG, SCOPA-PC, 
SPES/SCOPA motor and motor complications). All patients who used antiparkinsonian medication were 
assessed while they benefited from their medication. When exhaustion or off-periods were detected, 
patients were allowed to take a break or medication. For each patient, a levodopa dose equivalent (LDE) 
was calculated.25 
Statistical analyses
In the SPES/SCOPA, the items rest tremor, postural tremor, bradykinesia and rigidity are separately 
evaluated for the left and right arm. For the present analyses, scores of both sides both sides were 
added up, resulting in one score for each symptom. 
Exploratory and confirmatory analyses
The total group was randomly divided into two samples, which was expected to yield two approximately 
equally large groups. Next, an EFA with oblique rotation was performed on the first sample, using all 10 
items of the SPES/SCOPA-motor. The oblique rotation method was used, because factors emerging 
from the motor domain were expected to be correlated.26 The number of factors was determined 
by inspection of the scree plot and Kaiser’s criterion (i.e. eigenvalue>1). Data of the second sample were 
used for cross-validation. In structural equation modeling (SEM), relations between measured and proposed 
latent variables (factors) can be evaluated. CFA is a special case of SEM and tests how well data fit an a 
priori hypothesized model of variables that group together in factors.27 Based on the result of the EFA, a 
model was constructed. The chi-square test for goodness-of-fit was calculated. This test should be 
nonsignificant (P>0.05, indicating that the model does not significantly differ from the data), although 
it should be noted that the test is sensitive to sample size and to small to moderate discrepancies 
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of the data to normality.26,28 Therefore measures estimating the lack of fit (the root means square 
error of approximation (RMSEA) and the standardized root mean square residual (SRMR)) were also 
calculated, supplemented with a measure to test the model’s goodness of fit (comparative fit index 
(CFI)).29 RMSEA values >0.1 indicate a poor fit, <0.08 reasonable fit, and <0.05 good fit. The SRMR 
reflects a good fit if the value is <0.08. A CFI close to 0.95 is indicative of a good fit.28,29
 
Pearson correlations (r; two-tailed) were calculated to assess the correlation between each of the 
resulting motor factors and the other impairment domains of PD, and demographic and disease 
related variables. Correlation coefficients were defined as very weak (r=0.00-0.19), weak (r=0.20-
0.39), moderate (r=0.40-0.59), strong (r=0.60-0.79), or very strong (r=0.80-1.00).30 Multiple forward 
linear regression analysis with separate blocks was used to explore the contribution of the impairment 
domains to the motor factors, while taking differences in demographic and disease related variables 
into account (block 1: age, disease duration, LDE; block 2: impairment domains).
Statistics were performed in SPSS 16.0, except for CFA which was carried out with EQS 6.1 for 
Windows.31
Results
After excluding patients who underwent stereotactical surgery (N=18), data of 399 patients were 
available for analysis, of whom 344 had no missing values on any item of the SPES/SCOPA-motor. The 
mean (SD) age was 60.8 (11.6) years, the mean (SD) disease duration was 10.1 (6.2) years and the 
mean (SD) LDE was 570 (452) mg. EFA was performed on 171 patients, while CFA was performed 
on 173 patients. The samples did not differ with respect to age, disease duration, or LDE (age: mean 
difference -1.2, 95% CI -3.7 to 1.2; disease duration: mean difference -1.6, 95% CI -4.1 to 0.95; LDE: 
mean difference 51, 95% CI -45 to 147).
Table 1. Results of the exploratory factor analysis of the SPES/SCOPA motor section (oblique 
rotation)
Motor items SPES/SCOPA Factor 1 Factor 2 Factor 3 Factor 4










% of variance explained by factor 29.1 16.7 11.7 10.5
Factor loadings <0.4 have been omitted from the table. 
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Exploratory factor analysis 
The screeplot indicated a four-factor solution. Four factors had an eigenvalue >1, explaining 68.0% 
of the variance (factor 1: 29.1%, factor 2: 16.7%, factor 3: 11.7%, factor 4: 10.5%; see Table 1). 
Factor 1 consisted of items that relate to axial motor function, namely ‘rise from chair’, ‘gait’, and 
‘postural instability’. A second ‘axial’ factor (factor 2) consisted of the items ‘freezing during on’, 
‘speech’ and ‘swallowing’. ‘Rest tremor’ and ‘postural tremor’ grouped in factor 3, whereas ‘rigidity’ 
and ‘bradykinesia’ formed factor 4. 
Confirmatory factor analysis
Based on the four factors a model was constructed (Figure 1). The chi-square test was significant (χ2 
= 52.33, degrees of freedom = 29, P = 0.01). Other fit indices reflected a good fit: The CFI was 0.94, 
the RMSEA 0.07 (90% confidence interval 0.04 – 0.10) and the SRMR 0.06. 
Standardized solution of the model as tested in the confirmatory analysis. The circles represent the 
latent variables or factors; the arrows on the right point at the items (in the rectangles) of which the 
factors are composed; the numbers above the arrows represent the path coefficients (equivalent of 
factor loading in exploratory factor analysis); the arrows on the left indicate that intercorrelations 
between the factors were allowed, and the numbers indicate the magnitude of the intercorrelations.
Association between motor factors and demographic, clinical and disease related 
characteristics
Both axial factors showed significant weak to moderate correlations with most of the impairment 
domains. Both factors moderately correlated with autonomic symptoms. The first axial factor further 
showed moderate correlations with age, whereas the second axial factor moderately correlated with 
psychotic symptoms. The bradykinesia-rigidity factor only had weak or non-significant correlations, 
whereas the tremor factor hardly showed any significant correlation. In the multiple regression 
analysis, a total of 34% of the variance of the first axial factor was accounted for, with 21% being 
Figure 1. Model of factor structure of the SPES/SCOPA motor section
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explained by higher age and longer disease duration (block 1), and more autonomic symptoms, more 
depressive symptoms, and more cognitive impairment together accounting for the other 13% (block 
2). A total of 34% of the variance of the second axial factor was explained, with longer disease 
duration contributing 15% in the first block, and higher LDE, more severe autonomic symptoms, 
more psychotic symptoms, more severe dyskinesias, more depressive symptoms, and less severe 
nighttime sleep problems explaining the other 19% (Table 2). Only 3% of the variance of the tremor 
factor could be explained by longer disease duration and less severe sleep problems. More cognitive 
impairment, more autonomic symptoms, and less severe dyskinesias together accounted for the 9% 
explained variance of the bradykinesia-rigidity factor. 
Table 2. Regression analyses of the motor factors
Motor factor Independent variables * Beta ‡ R2
Axial 1 a,b Age 0.21 0.14
Disease duration 0.17 0.07
Autonomic symptoms 0.24 0.09
Depressive symptoms 0.17 0.03
Cognitive impairment 0.12 0.01
Total - 0.34
Axial 2 a,c Disease duration 0.15 0.15
LDE 0.14 0.04
Autonomic symptoms 0.18 0.09
Psychotic symptoms 0.14 0.02
Dyskinesias 0.15 0.02
Depressive symptoms 0.17 0.01
Sleep problems -0.11 0.01
Total - 0.34
Tremor a Duration 0.13 0.01
Sleep problems -0.12 0.02
Total - 0.03
Bradykinetic-rigid a Cognitive impairment 0.23 0.06
Autonomic symptoms 0.16 0.02
Dyskinesias -0.14 0.01
Total - 0.09
* Variables are ordered in the table as they appeared in the model.
‡ Standardized beta.
a Multiple forward linear regression analysis with variables entered in two blocks: block 1: age, disease 
duration, levodopa dose equivalent; block 2: cognition, autonomic symptoms, depressive symptoms, 
psychotic symptoms, sleep problems, daytime sleepiness, motor fluctuations, dyskinesias.
b axial 1: factor consisting of the items ‘rise’, ‘gait’, ‘postural instability’
c axial 2: factor consisting of the items ‘freezing’, ‘speech’, ‘swallowing’
LDE; levodopa dose equivalent.
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Discussion
Exploring and characterizing interrelations of assumed different clinical features of disease may 
contribute to the understanding of shared underlying mechanisms. Four motor factors were 
identified by EFA and confirmed by CFA in an independent sample. All factors showed different 
correlation patterns with other characteristics important in PD, thus underscoring their differential 
nature. Interestingly, two factors related to axial motor symptoms and collectively explained 46% 
of the variance of the motor items. The factor that explained most of the variance was related to 
the so-called PIGD component of PD and included ‘rise from chair’, ‘gait’, and ‘postural instability’. 
Previous studies that applied different rating scales have identified a similar PIGD factor, in spite of 
the application of different rating scales. The consistency of these findings thus underscores the 
importance of this motor component of PD.14-16 
In contrast to the other studies, we also found a second axial factor, consisting of ‘freezing’, 
‘speech’, and ‘swallowing’. This contrast may simply be explained by the fact that in the UPDRS 
these items are part of the ADL section, which was not included in the factor analyses of previous 
studies. The relation between speech and swallowing most likely reflect a shared impairment of 
oral-pharyngeal motor control. The association with freezing is less obvious. However, in one study 
speech in addition to gait, consistently was associated with freezing and with the risk of developing 
freezing.32 Additionally, freezing frequency correlated with speech and writing in patients who were 
“on”, while improvement of freezing frequency by levodopa strongly correlated with improvement 
of tremor and speech.33 In both studies swallowing was not analyzed.
Both axial factors correlated with each other and showed similar correlations with disease duration, 
autonomic symptoms, and depression. Although our findings suggest some commonality between 
both axial factors, regression analyses also showed clear differences. The axial factor with PIGD items 
was related to higher age and more cognitive impairment, which is in line with previous studies.6,7,34 
The second axial factor showed relations with dopaminergic medication and complications of therapy 
(psychotic symptoms and dyskinesias). Because dopaminergic treatment may provoke freezing,35,36 
the association between this axial factor and complications of therapy is not unexpected. Consistent 
with findings of other studies, a tremor factor was identified.13,15,16 This factor clearly behaved as the 
most independent component of the motor spectrum, as illustrated by the lower correlations with 
other factors and the lack of relations with most nonmotor impairments.  
Finally we identified a bradykinesia-rigidity factor, which was described in one earlier study.15 This 
factor was marginally explained by other disease related variables. However, relations with other 
domains may be masked by a generally stronger effect of dopaminergic medication on bradykinesia 
and rigidity in comparison with other motor features.37 
Of previous studies that performed factor analysis on motor symptoms in PD, some analyzed tremor, 
bradykinesia and rigidity separately for each extremity,14,16 while others did not.13,15 Stebbins et al. used 
exploratory factor analysis and found side sensitivity for bradykinesia, but not for tremor and rigidity. 
Stochl et al. performed a confirmatory factor analysis and found two factors reflecting laterality 
(right and left) in addition to five factors that reflected symptoms. Since PD may present with an 
asymmetrical appearance of tremor, bradykinesia, or rigidity, which persists over the disease course,38 
the finding of a laterality factor is not unexpected. To date it is unclear if laterality is informative with 
respect to distinct motor subtypes or their underlying biological constructs. Anomalies of asymmetry 
of motor impairments were found in 11% of the patients with PD, including a rest tremor most 
pronounced in one upper limb and the contralateral lower limb, rest and postural tremor most 
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pronounced in opposite extremities, and unilateral dominance of rigidity, bradykinesia and rest 
tremor, followed by development of predominance of all three features on the contralateral side.39 
Asymmetric manifestations of the disease have been suggested to be stochastically determined and 
not by genetic, environmental, structural or neurochemical causes.38 Aim of our study was therefore 
to detect patterns of interrelations between the various motor symptoms in PD irrespective of side 
differences.
Items that involve motor features that are responsive to levodopa will likely have been scored as 
less severe compared to the situation in which they did not benefit from their medication (i.e., were 
‘off’) and this may have altered the strength of the correlations between items. However, the overall 
effect on the factor structure is probably limited, because Stebbins et al., who performed factor 
analyses both in the ‘on’ and ‘off’ phase, showed that both situations resulted in an identical factor 
structure.14,40
In conclusion, we identified four distinct components of the motor spectrum of PD through a data-
driven approach. Based on their different relations with demographic characteristics and clinical 
domains of the disease, these components may reflect the different nature of causes, including 
disease process, aging and dopaminergic treatment. Additionally, these motor components may 
facilitate future research aiming to identify clinical subtypes of PD.
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Abstract
Objective: To evaluate the presence and nature of patterns of coherency among the motor and 
nonmotor domains in Parkinson’s disease (PD) and to examine which clinical parameters are related 
to the potential patterns.  
Methods: A cohort of 397 PD patients was randomly divided into two samples. Exploratory 
factor analysis (EFA) was performed on the motor and nonmotor symptoms in PD in the first sample. 
Findings of the EFA were used to construct a model which was tested in the second sample by 
confirmatory factor analysis. Multiple regression analyses on the resulting factors were performed to 
evaluate the influence of clinical parameters upon these factors.
Results: Four factors were identified. The first and strongest factor (cognitive impairment, 
autonomic dysfunction, psychotic symptoms, depression, daytime sleepiness, and axial symptoms) 
reflected advancing disease. Another factor largely reflected motor complications of therapy and was 
related to dopaminergic medication. The other two factors reflected sleep/depression and tremor/
bradykinesia/rigidity, and were only marginally related to disease severity or medication.
Conclusions: The motor and nonmotor features in PD can be characterized by four distinct 
patterns of coherency, which provide insight in the contributions of the primary disease process 
and anti-parkinsonian medication to the broad clinical spectrum of PD. One factor, consisting of 
predominantly nonmotor symptoms together with axial features, clearly reflected disease severity 
and may provide a new basis for monitoring disease progression in PD.
Introduction
Parkinson’s disease (PD) encompasses not only a variety of well-known motor features, but also 
a broad spectrum of nonmotor symptoms, including cognitive impairment, psychotic symptoms, 
depression, sleep disorders, and autonomic dysfunction.1 However, when considering the full 
spectrum of the disease, there is still limited information on the coherency of the various motor 
and nonmotor symptoms. This may be partly due to the fact that past research mainly focused 
on the motor signs of PD as well as to the limited availability of PD specific and clinimetric sound 
measurement instruments to assess the nonmotor impairments.2 From more recent studies that 
characterized specific domain interrelations, it is apparent that differential relations exist between 
the various motor and nonmotor domains.1,3-5 However, in these studies not all impairment domains 
were studied simultaneously, which is required to unravel domain coherency. Knowledge on the 
coherency of motor and nonmotor domains is important because it may suggest underlying constructs 
that provide new insight in the contributions of the primary disease process and anti-parkinsonian 
medication to the broad clinical symptom profile of PD. 
In the PROPARK study valid and reliable instruments for each of the relevant impairment domains 
have been applied simultaneously in a large cohort of patients with PD (www.scopa-propark.eu). As 
this approach allows a more comprehensive view of domain interrelations, the aim of this study is to 
evaluate the presence and nature of patterns of coherency among the motor and nonmotor domains 
in PD and to examine which clinical parameters are related to the potential patterns.
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Method
Study design 
The study is part of the “PROfiling PARKinson’s disease” (PROPARK) study, a longitudinal cohort study 
of patients with PD, who are profiled on phenotype, genotype, disability and global outcomes of 
health using valid and reliable assessment instruments for PD. Findings obtained from the first annual 
evaluation of 415 patients who were assessed between May 2003 and March 2006 were used for 
the present analysis.
Study participants
All patients fulfilled the United Kingdom Parkinson’s Disease Society Brain Bank criteria for idiopathic 
PD.6 Patients were recruited from outpatient neurology clinics of university and regional hospitals in the 
western part of The Netherlands. The majority of the patients were assessed at the Leiden University Medical 
Centre (LUMC); patients who were unable to come to the hospital were assessed at home. Age-at-onset and 
disease duration are important determinants of disease course in PD and are related to various manifestations 
of the disease.7,8 To obtain an adequate distribution of these characteristics across the cohort, we aimed 
to construct four strata of 100 patients each, based on age-at-onset (onset of the first symptoms as 
perceived by the patient; < / > 50 years) and disease duration (<  / > 10 years). The study was 
approved by the medical ethical committee of the LUMC and all participants gave informed consent.
Outcome measures
Information on clinical and sociodemographic variables was obtained and included age, age-at-
onset, disease duration, disease severity (measured with the Hoehn and Yahr (H&Y) scale),9 and 
medication. Levodopa equivalent units were calculated for levodopa and dopamine agonists.10
The following domains were assessed: motor signs and motor complications (SPES/SCOPA, sections 
motor evaluation (ME) and motor complications (MC)),11 cognitive impairment (SCOPA-COG),12 
psychotic symptoms (SCOPA-PC, items 1-5),13 autonomic dysfunction (SCOPA-AUT, items 4-6, 
8-16),14 depressive symptoms (Beck Depression Inventory (BDI))15, nighttime sleep problems (NS) 
and daytime sleepiness (DS) (SCOPA-SLEEP sections NS and DS).16 Cognitive impairment, autonomic 
dysfunctioning, and motor signs were evaluated as either total or subscores. Subdomains of the 
SCOPA-COG include memory, attention, executive functioning, and visuospatial functioning. From 
the SCOPA-AUT, subscores were calculated for constipation (items 4-6), urinary dysfunction (items 
8-13), and cardiovascular dysfunction (items 14-16). We excluded domains from the SCOPA-AUT 
that were less relevant (pupillomotor), were composed of opposite items (thermoregulatory) or 
yielded too many missing values (sexual dysfunction, because patients indicated these items were 
“not applicable”). Motor signs were evaluated by subdomains, resulting from a previously performed 
factor analysis on the SPES/SCOPA-motor,17 and included tremor (rest and postural tremor), 
bradykinesia and rigidity, axial symptoms (rise, gait, postural instability), and a second axial factor 
(freezing, swallowing, speech).  
Instruments were either self-completed (SCOPA-AUT, BDI, SCOPA-SLEEP) or administered by trained 
research associates (SCOPA-COG, SCOPA-PC, SPES/SCOPA). Domains and subdomain scores of the 
SCOPA-COG were inversed to arrange that all scores were in the same direction, with higher scores 
reflecting more severe impairment. For reasons of comparability, all patients who used anti-parkinsonian 
medication were assessed while they benefited from their medication. When exhaustion or off-periods 
were detected, patients were allowed to take a break or medication. 
Opmaak 2.indd   59 21-09-12   15:32
60  | Patterns of motor and nonmotor features in Parkinson’s disease
Statistical analysis
The total group was randomly divided into two subgroups. In the first sample, the impairments were 
subjected to an exploratory factor analysis (EFA) with oblique rotation. Since factors emerging from 
the spectrum of PD domains are expected to be correlated, an oblique rotation, which allows for 
correlation of factors, was applied. 18 The results of the EFA in the first sample were next used 
to construct a model that was tested for model fit in the second sample, using confirmatory factor 
analysis (CFA). To evaluate how well the data fitted the model measures estimating the lack of fit (the 
root means square error of approximation (RMSEA) and the standardized root mean square residual 
(SRMR)) were calculated, supplemented with a measure to estimate the model’s goodness of fit 
(comparative fit index (CFI)).19 RMSEA values >0.1 indicate poor fit, whereas values <0.08 and <0.05 
indicate reasonable and good fit, respectively. The SRMR reflects a good fit if the value is <0.08. A 
CFI close to 0.95 is indicative of a good fit.19,20 Factor loadings >0.32 were considered poor, >0.45 
fair, >0.55 good, >0.63 very good, and >0.71 excellent, which correspond with squared variances of 
0.1, 0.2, 0.3, 0.4, and 0.5, respectively.21
Multiple forward linear regression analysis with two blocks was used to explore the relation between 
the different factors and the disease process and medical therapy, while removing all variation due to 
demographic characteristics by entering age and sex separately in block 1 (block 1: age, sex; block 2: 
disease duration, Hoehn and Yahr stage (H&Y), levodopa dose (LDE L-dopa), agonist dose (LDE DA)). 
Age-at-onset was not entered in the regression model, because it is determined by including age and 
disease duration and thus could have resulted in collinearity.
Statistics were performed with SPSS 14.0, except for CFA which was carried out with EQS 6.1 for 
Windows.22
Table 1. Patient characteristics
Characteristics Total group Sample EFA Sample CFA P
N 397 196 201  -
men/women, N (% men) 253/144 (64%) 134/62 (68%) 119/82 (59%) 0.06 a
Age, yrs, mean (SD) 61.2 (11.5) 60.9 (10.9) 61.6 (12.0) 0.58 b
Age onset, yrs, mean (SD) 51.0 (11.8) 50.8 (11.5) 51.2 (12.2) 0.71 b
Disease duration, yrs, median (IQR) d 9.2 (5.2-14.0) 9.6 (5.2-14.1) 8.9 (5.0-13.9) 0.86 c
H&Y stage, median (IQR) 2 (2-3) 2 (2-3) 2 (2-3) 0.66 c
Patients on L-dopa, N (%) 264 (67%) 131 (67%) 133 (67%) 0.89 a
Patients on DA, N (%) 276 (70%) 144 (74%) 132 (66%) 0.09 a
LDE L-dopa, mg, median (IQR) d 300 (0-540) 300 (0-600) 300 (0-500) 0.70 c
LDE DA, mg, median (IQR) d 188 (0-375) 200 (0-400) 180 (0-329) 0.27 c
a) Chi-square 
b) Independent samples t-test 
c) Mann-Whitney U-test
d) Data were not normally distributed, therefore median (IQR) is presented.
EFA; exploratory factor analysis, CFA; confirmatory factor analysis, IQR; interquartile range, H&Y; 
Hoehn and Yahr, L-dopa; levodopa, DA; dopamine agonists
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Results
Eighteen patients who underwent stereotactical surgery were excluded from the analysis. 
Characteristics of the 397 patients who remained for analysis, and of the subsamples used for 
exploratory and confirmatory analysis, are presented in table 1. The two subsamples did not 
significantly differ on any of the characteristics (all P-values >0.05).
Exploratory analysis
An initial EFA of all domains, including the subdomains of cognitive impairment (memory, attention, 
executive and visuospatial functioning) autonomic dysfunctioning (constipation, urinary dysfunction, 
cardiovascular dysfunction) and motor signs (tremor, bradykinesia/rigidity, two axial factors), showed 
that the subdomains of cognition and autonomic impairment grouped together, but the motor 
subdomains did not. Therefore a second EFA was performed in which the total scores of cognitive 
impairment and autonomic dysfunction, and the subdomain scores of motor signs were included. 
Four factors with an eigenvalue >1 were identified, which together explained 62% of the variance 
(Table 2). These factors were similar to the factors resulting from the first EFA. The first factor, 
explaining 31% of the variance, comprised psychotic symptoms, daytime sleepiness, autonomic 
dysfunction, and cognitive impairment, depression and both axial symptoms. Nighttime sleep 
problems, motor fluctuations and depression clustered in the second factor, and explained 12% 
of the variance. The third factor, comprising dyskinesias, motor fluctuations, and axial symptoms 
2 (freezing, swallowing, speech), explained 11% of the variance. Factor four explained 9% of the 
variance and included the remaining motor subdomains, that is, tremor and bradykinesia/rigidity. 
Three domains showed dual loadings, namely depression (factor 1 and 2), axial symptoms 2 (factor 
1 and 3) and motor fluctuations (factor 2 and 3).
Table 2. Exploratory factor analysis of impairment domains 





Axial symptoms1 * 0.61 0.45
Axial symptoms2 ** 0.60 0.56
Depression 0.60 0.61
Nighttime sleep problems 0.84




% of variance 31 12 11 9
Structure matrix of exploratory factor analysis with oblique rotation. Factor loadings <0.45 have been 
omitted. Four factors with eigenvalue >1, explaining 61.9% of the variance. 
* Axial symptoms 1: Rise, gait, postural instability;
** Axial symptoms 2: Freezing, speech, swallowing.
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Confirmatory analysis
A model for CFA was constructed, based on the results from the second EFA (factor loadings 
>0.55). The fit of this model was insufficient. A model with good fit was obtained when cognitive 
impairment was allowed to load on factor 2 and axial symptoms 2 was allowed to load on factor 
4 (Figure 1). The CFI of this model was 0.95, while the SRMR was 0.05 and the RMSEA 0.06 (95% 
CI 0.03-0.08). The factor loadings of axial symptoms 2 on factor 1 and 4, and the factor loading 
of motor fluctuations on factor 2 had a positive, albeit non-significant, contribution to the fit of 
the model. The factor loadings of the variables loading on factor 1 were in a similar range of very 
good (psychotic symptoms, autonomic dysfunction, and axial symptoms 1) to excellent (cognitive 
impairment). The loading of depression on factor 1 was fair while the loading of daytime sleepiness 
on this factor was poor. Factor 2 was mainly determined by sleep, which had an excellent factor 
loading, while depression and cognition poorly loaded on this factor. Notably, cognitive impairment 
had a negative loading on factor 2. Of the three variables loading on factor 3, the loading for 
dyskinesias was excellent, while these were good for motor fluctuations, and nearly fair for axial 
symptoms 2. Rigidity and bradykinesia most strongly determined factor 4 with an excellent factor 
loading, whereas the factor loading of tremor was poor.
Figure 1. Model of factor structure of all impairment domains of Parkinson’s disease
Standardized factor loadings are indicated next to the arrows. Non-significant factor loadings with a 
positive contribution to the fit of the model are not displayed in the figure (axial symptoms 2 on factor 
1 and 4; motor fluctuations on factor 2).
* Axial symptoms 1: Rise, gait, postural instability;
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Table 3. Regression analyses of the factors
Independent variables * Beta ‡ P-value 
beta
R2
Factor 1 a,b Age 0.21 0.00 0.18
H&Y stage 0.43 0.00 0.23
LDE L-dopa 0.14 0.00 0.03
Disease duration 0.14 0.00 0.01
Total - 0.45
Factor 2 a,c Age -0.20 0.00 0.03
Sex -0.14 0.01 0.02
LDE DA 0.15 0.01 0.03
LDE L-dopa 0.15 0.01 0.02
Total - 0.10
Factor 3 a,d Age -0.08 0.06 0.02
LDE L-dopa 0.44 0.00 0.31
Disease duration 0.26 0.00 0.09
LDE DA 0.14 0.00 0.01
H&Y stage 0.13 0.00 0.01
Total - 0.44
Factor 4 a,e Age 0.01 0.82 0.02
Sex 0.19 0.00 0.01
H&Y stage 0.30 0.00 0.08
LDE DA -0.13 0.01 0.02
Total - 0.13
* Variables are ordered in the table as they appeared in the model.
‡ Standardized beta.
a Multiple forward linear regression analysis with variables entered in two blocks: block 1: sex, age; 
block 2: levodopa dose equivalent levodopa, levodopa dose equivalent dopamine agonists, Hoehn and 
Yahr stage, disease duration.
b Factor 1, including psychotic symptoms, autonomic dysfunction, daytime sleepiness, axial symptoms 
(rise, gait, postural instability), cognitive impairment, depressive symptoms.
c Factor 2, including nighttime sleep problems, depressive symptoms, cognitive impairment.
d Factor 3, including motor fluctuations, dyskinesias, axial symptoms (freezing, speech, swallowing).
e Factor 4, including bradykinesia and rigidity, tremor.
LDE; levodopa dose equivalent, L-dopa; levodopa, DA; dopamine agonists, H&Y; Hoehn and Yahr. 
Relations with disease and medication related variables
In the multiple regression analyses controlling for age and sex, 45% of the variance of factor 1 
was explained, with H&Y stage contributing 23%. A total of 44% of the variance of factor 3 was 
accounted for, with LDE L-dopa explaining 31% and disease duration 9%. Only 10% of the variance 
of factor 2 and 13% of factor 4 was explained (Table 3).
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Discussion
Identification of factors among motor and nonmotor impairment domains may aid in unraveling 
the nature of underlying constructs. Using EFA, we identified four factors in the spectrum of motor 
and nonmotor symptoms in our sample of patients with PD. With only minor modifications, this 
factor structure was confirmed by CFA in an independent sample, thereby strengthening the results. 
The first and strongest factor comprised most of the nonmotor domains. The main contributors to 
this factor were cognitive impairment, autonomic dysfunction, psychotic symptoms and the axial 
symptoms that reflect Postural Instability Gait Difficulty (PIGD; rise, gait and postural instability). 
Daytime sleepiness and depressive symptoms had a smaller contribution to this factor. The second 
factor was mainly characterized by sleep disturbances and showed a moderate contribution of 
depressive symptoms and cognitive impairment. The third factor comprised both types of motor 
complications with a smaller additional contribution of the axial symptoms freezing, speech, and 
swallowing. The classical motor features of PD (tremor, bradykinesia and rigidity) grouped together 
in the fourth factor. 
In trying to understand the nature of the encountered patterns, multiple regressions analysis was 
used to evaluate relations between the factors and variables that reflect disease severity and duration 
as well as dopaminergic treatment. This approach revealed H&Y stage as the variable most strongly 
related to factor 1 with negligible contributions of LDE L-dopa and disease duration (1-3%). LDE 
L-dopa was the variable most strongly related to factor 3 with disease duration showing a small (9%) 
contribution. Notably, for both factors, more than half of the variance is unexplained. The variables 
in the regression model together explained only a negligible proportion (10-13 %) of the variance 
of factors 2 and 4.
The coherence of the domains in factor 1 corroborates the results from previous studies.23 The 
relation with H&Y stage and to a lesser extent disease duration most likely indicate that symptoms 
in this factor cumulate with increasing disease severity or Lewy body pathology.24 The load of Lewy 
body pathology is related to the alpha-synuclein gene dosage, which in turn is also influenced by 
aging.25 In earlier studies, visual hallucinations, frequent falls, and cognitive impairment have all been 
found to occur at a similar time to death, which was not proportional to disease duration.23,26 If, in 
the development of these symptoms, time to death is a more important determinant than disease 
duration, age is expected to be more closely related to these symptoms than disease duration. We 
indeed found that age explained 18% of the variance in factor 1, while the relation with disease 
duration was negligible. 
Factor 3 was predominantly related to LDE L-dopa, whereas a smaller part was explained by disease 
duration. Total daily dose, duration of exposure, and age at initiation of L-dopa, together with disease 
severity, are well known risk factors of motor complications.27,28 The relation between medication 
and freezing, speech and swallowing is somewhat unexpected, but in agreement with findings of 
others.29,30 In a previous factor analysis on motor signs of PD, axial symptoms presented as two 
separate factors, namely one reflecting rise, gait and postural instability, and the other reflecting 
freezing, speech and swallowing.17 Our current findings showed a differential behaviour of both 
axial factors with respect to their contribution to the four factors and thus may indicate that they 
represent distinct motor components of PD.
The relation between sleep and depression, as found in factor 2, has been found in several studies.31-33 
A negative relation between sleep and cognition has also been reported previously.4 Of the 10% 
variance of this factor that could be explained, half was accounted for by LDE L-dopa and LDE 
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DA. The relation between insomnia and dopaminergic medication has been found by others32,33 
and may possibly be due to the negative influence of dopaminergic medication on sleep depth or 
REM sleep.34  In line with findings from other studies, no relation emerged between this factor and 
disease severity.31-33 Possibly this is explained by the finding that in PD, insomnia is an inconsistent 
and reversible complaint.31 The dual loading of depression on factors 1 and 2 is most likely explained 
by the multifactorial etiology of depression.35,36
Factor 4, comprising the motor signs tremor, bradykinesia and rigidity, showed a marginal correlation 
with DA dose, which is in line with previous findings.37  A similar marginal correlation was found for 
disease severity, although others have reported a stronger association.38 Because bradykinesia and 
rigidity are responsive to dopaminergic treatment, these marginal correlations may reflect a masking 
effect of dopaminergic medication.39 Additionally, our findings again underscore that tremor has a 
distinct behavior within the motor spectrum of PD.38,40
In the present study, the full spectrum of motor and nonmotor symptoms of PD was evaluated in 
a large cohort, using measurement instruments specifically developed for PD. We found distinct 
patterns of domain coherency among motor and nonmotor symptoms, with the first and strongest 
factor (cognitive impairment, autonomic dysfunction, psychotic symptoms, PIGD, daytime sleepiness 
and depressive symptoms) reflecting advancing disease. 
Hitherto, the severity and longitudinal course of PD is evaluated by the Hoehn and Yahr staging 
system, which, from a conceptual point of view, is a peculiar mixture of impairments and disabilities.9 
Stages are determined by the presence of tremor, bradykinesia or rigidity on one or both sides of the 
body in the early phase of the disease, and by postural instability and the degree of disability in the 
more advanced stages. In view of the growing awareness that the clinical spectrum of PD is much 
broader than motor signs only, this staging system does not do justice to the clearly more complicated 
nature of the disease. In the present study disease severity was found to be best characterized by the 
nonmotor domains and PIGD motor features that constitute factor 1. Together these domains may 
provide a better basis of a future disease severity staging system. Additionally, motor complications 
as reflected in the third factor, are an important consequence of the treatment in PD. Since motor 
complications are only marginally related to disease severity, this domain likely is better evaluated 
on a separate axis. 
Factors 2 (sleep and depression) and 4 (bradykinesia, rigidity and tremor), though distinct, are not 
related to either disease severity or complications of therapy. Therefore, these domains have limited 
applicability in a disease severity staging system. However, information of these domains may have 
important consequences for disease management and for future studies on patient subtypes. Further 
research in independent samples is needed to confirm our results. 
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Abstract
Objective: The clinical heterogeneity of Parkinson’s disease (PD) may point at the existence of 
subtypes. Since subtypes likely reflect distinct underlying etiologies, their identification may facilitate 
future genetic and pharmacotherapeutic studies. Aim of this study is to identify subtypes by a data-
driven approach applied to a broad spectrum of motor and nonmotor features of PD.
Methods: Data of motor and nonmotor PD symptoms were collected in 802 patients in two 
different European prevalent cohorts. A model-based cluster analysis was conducted on baseline data 
of 344 patients of a Dutch cohort (PROPARK). Reproducibility of these results was tested in data of 
the 2nd annual assessment of the same cohort, and validated in an independent Spanish cohort (ELEP) 
of 357 patients. The subtypes were subsequently characterized on clinical and demographic variables. 
Results: Four similar PD subtypes were identified in two different populations and are largely 
characterized by differences in the severity of nondopaminergic features and motor complications: 
subtype 1 was mildly affected in all domains, subtype 2 was predominantly characterized by severe 
motor complications, subtype 3 was affected mainly on nondopaminergic domains without prominent 
motor complications, while subtype 4 was severely affected on all domains. The subtypes had largely 
similar mean disease durations (non-significant differences between three clusters), but showed 
considerable differences with respect to their association with demographic and clinical variables. 
Conclusions: In prevalent disease, PD subtypes are largely characterized by the severity of 
nondopaminergic features and motor complications, and likely reflect complex interactions between 
disease mechanisms, treatment, aging, and gender. 
Introduction
Parkinson’s disease (PD) is generally known as a movement disorder, but there is an increasing 
awareness that the clinical spectrum of PD encompasses also many nonmotor domains like cognition 
and autonomic function.1 PD patients exhibit conspicuous differences in the disease profile and 
progression rate.2 This clinical heterogeneity may indicate the existence of subtypes. Identification 
of subtypes is important as homogeneous groups likely reflect stronger clinical, pathological, and 
genetic coherence, which, in turn, may facilitate our understanding of involved biological pathways. 
This may ultimately lead to tailored treatment strategies. 
In studies on PD subtypes patients have often been classified according to predefined criteria (e.g. 
young versus old age at onset (AO), or dominance of tremor versus bradykinesia/rigidity), after which 
other clinical variables were compared between the resulting groups.2 Alternatively, subtypes may 
be identified through a data-driven approach like cluster analysis (CA), in which the profile of the 
subtypes arise from the data without a priori clinical assumptions.  
In a systematic review, seven studies were identified that used CA to identify subtypes in the 
broad clinical spectrum of PD.3 The majority of those studies identified a subtype with ‘old age-
at-onset and rapid disease progression’ and a subtype characterized by ‘young age-at-onset and 
slow disease progression’. However the results of these studies were difficult to compare because 
of methodological differences. Studies focused on different PD domains, which were occasionally 
combined with other variables such as AO and dopaminergic therapy, resulting in conceptually 
unclear cluster solutions. Further, the applied CA techniques showed some limitations.3 The aim of 
the present study is to identify PD subtypes based on motor and nonmotor features of PD, by using 
a data-driven approach applied to data of two large independent European cohorts. 
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Method
Patients 
Data were obtained from two European longitudinal cohorts, the PROfiling PARKinson’s disease 
cohort (PROPARK; n=415; www.scopa-propark.eu) and the Estudio Longitudinal de pacientes con 
Enfermedad de Parkinson cohort (ELEP; n=387).4 Data of the first and second annual assessment 
of the PROPARK cohort were collected between May 2003 and April 2007. Data of first annual 
assessment of the ELEP cohort were collected between March and December 2006.  
Patients in both cohorts fulfilled the United Kingdom PD Society Brain Bank criteria for idiopathic 
PD.5 The recruitment procedure of the PROPARK cohort has been described in detail elsewhere.6 
In short, patients were recruited from outpatient departments of three university and six regional 
hospitals, and assessed at the Leiden University Medical Centre. Four equally large strata based on 
AO (</>50 years) and disease duration (</>10 years) were constructed across the cohort to ensure 
an adequate distribution of factors that are considered to be important determinants of the disease 
course. Patients in the ELEP cohort were assessed at 20 centers in Spain. Here, six equally large strata 
were constructed based on sex, AO (30-60/>60 years), and disease duration (</>5 years). In both cohorts 
AO was defined as onset of first symptom(s) as perceived by the patient. Patients who underwent 
stereotactic surgery were excluded since this intervention may influence the expression of the 
phenotype. No other selection criteria were applied. All patients gave written informed consent. Studies 
were approved by the medical ethics committees of the Leiden University Medical Centre (PROPARK), 
and the Research Committee of the Carlos III Institute of Public Health and the Clinical Research 
Ethics Committee of the Hospital de la Princesa, Madrid (ELEP).
Measurement instruments
Except for depression, patients in both cohorts were assessed with the same instruments, which 
have been described in more detail elsewhere.7 The following features were assessed: Motor symptoms 
and Motor Complications (MCs) (SPES/SCOPA sections Motor and Motor Complications), cognitive 
functioning (SCOPA-COG), autonomic symptoms (SCOPA-AUT), psychotic symptoms (SCOPA-PC), 
items 1-5), nighttime sleep problems and excessive daytime sleepiness (SCOPA-SLEEP), and depressive 
symptoms (PROPARK: Beck Depression Inventory (BDI); ELEP: Hospital Anxiety and Depression Scale 
(HADS)8). Based on results of our previous study9 motor features were evaluated by a tremor factor 
including rest and postural tremor, a factor consisting of bradykinesia and rigidity, and two axial 
factors, i.e. one factor comprising rise, gait, and postural instability, reflecting what is commonly 
known as Postural-Instability-Gait-Difficulty (PIGD), and one factor comprising freezing during on, 
speech, and swallowing (FOSS). Autonomic dysfunction was evaluated with the gastrointestinal, 
urological, and cardiovascular items (4-6, 8-16) of the SCOPA-AUT, since these items were 
considered most relevant for phenotyping. Higher scores reflect poorer function for all scales except 
the SCOPA-COG; scores of this latter scale were inversed to facilitate interpretability. Patients using 
antiparkinsonian medication were assessed in “on” state. For each patient, a total levodopa (L-dopa) 
dose equivalent (LDE) was calculated.10 
Statistical analysis 
If 25% or more of the items of a scale was missing, this patient was excluded from statistical 
analyses. If, for a particular patient, less than 25% of the items of a scale were missing, missing data 
Opmaak 2.indd   71 21-09-12   15:32
72  | Clinical subtypes of Parkinson’s disease
were imputed by the mean value of the nonmissing items of that scale of that patient. 
Because severity of PD features increases with longer disease duration and, thus, may act as a 
potential confounder in the process of identifying distinct phenotypes, each variable was adjusted 
for disease duration: for each clinical feature the residual value was obtained from a linear regression 
with the clinical feature as the dependent and disease duration as an independent variable. Finally, 
all variables were transformed into z-scores to obtain scale invariant outcomes. 
Cluster analysis
To identify subtypes we performed a model-based CA on data of PROPARK year 1.  Clusters were 
tested for reproducibility in data of PROPARK year 2. The selected model was validated in data of 
the ELEP cohort by comparing the characteristics of the same model as selected in PROPARK year 1. 
Model-based CA assumes that the dataset is built up from a number of normal distributions. In 
model-based CA the relative model fit of different models varying in complexity (i.e., with respect to 
volume, shape, and orientation, which may either be equal or variable) is estimated. In the simplest 
model the clusters are spherical and have an equal volume and shape, while more complex models 
allow more variability between clusters. For reasons of generalizability, and in view of the size of 
the cohort, we focused on the five least complex clustering models with 3, 4, and 5 clusters; fifteen 
models in total. A Bayesian Information Criterion (BIC) is provided, which is a likelihood-based 
measure that indicates which clustering model and number of clusters have a maximized fit with 
a minimal number of parameters. The models are estimated with the Expectation Maximization 
algorithm. First, initial parameters of the model are estimated, after which patients’ probabilities for 
a cluster membership are estimated. Based on these probabilities model parameters are re-estimated. 
This iterative process is continued until the model no longer improves.11-13
Since any iterative method may end in a local optimum, rather than the optimum of all possible 
solutions, the Expectation Maximization algorithm was repeated 50 times with randomly chosen 
starting points, after which the optimal model was selected for each clustering model. Although 
model-based CA shares similarities with k-means CA, several aspects are specific for model-based 
CA. First, patients are not allocated to one cluster, but assigned to a cluster according to a probability. 
Second, there are no strict boundaries between clusters, they may overlap. Third, in contrast to 
k-means where clusters are always spherical, this method allows more flexibility for clusters to vary 
in size, shape, and orientation. Various clustering models of increasing complexity are simultaneously 
estimated for any number of clusters. Fourth, a fit statistic is provided to select the optimal model 
and optimal number of clusters. 
Selection of the optimal model and number of clusters for data of PROPARK year 1 was guided by 
BIC; models with a 5% lower BIC than the optimal model were also considered. 
To warrant stability of the cluster solution the selection of the model was further guided by the 
following considerations: 
1. Models with stronger associations between clustering models of different complexity and between 
the 3, 4, and 5-cluster solutions of models with the same complexity, were preferred over models 
with less strong associations. This was tested with Cramer’s V. 
2. The cluster profiles and patient’s cluster allocation in data of the first annual assessment were 
evaluated for reproducibility in data of the second annual assessment for each of the fifteen models. 
Models with higher reproducibility were preferred. 
To obtain clinically meaningful cluster results model selection was further guided by the following 
considerations: 
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3. Simpler clustering models were preferred over more complex clustering models to avoid the risk 
of overfitting and increase the generalizability to data of other cohorts. 
4. Models with very small clusters (<5% of the total group) were discarded, since they carry the risk 
of reflecting outliers. 
Caracterization of clusters
Cluster profiles were graphically displayed in heatmaps. Clusters were characterized for clinical-, 
demographic-, and disease related variables using data of PROPARK year 1. Differences between 
clusters were evaluated using ANOVA and Chi-square tests, using Bonferroni correction for multiple 
testing. A P-value <0.05 was considered significant.  
To evaluate which features best discriminated the clusters of the PROPARK and ELEP cohort, 
a discriminant analysis was performed with the clusters as dependent and the PD features as 
independent variables. A second discriminant analysis was performed on the PROPARK cohort with 
demographic- (age and sex) and disease-related (AO, disease duration, and LDE) as independent 
variables. 
CAs and cluster visualization were performed with SubtypeDiscovery 1.11 (https://gforge.nbic.nl/
projects/subtypediscover/) in R 2.7.0 (www.r-project.org). Other statistical analyses were performed 
using SPSS 16.0 (SPSS Inc, Chicago, IL, USA). 
Results
Data of 344 patients (1st assessment) and 276 patients (2nd assessment) of the PROPARK cohort and 
357 patients of the ELEP cohort were available for analysis (Figure 1, Table 1). A total of 48 (1%) 
values were imputed to replace missing values of 45 (13%) of the patients in the dataset of the first 
PROPARK assessment; 46 (1%) of the values were imputed to replace missing values of 38 (14%) 
patients in the dataset of the second PROPARK assessment. No data were missing for the ELEP 
cohort. 
415 pt PROPARK - cohort
18
53 pt dropped out
276 pt in cluster
analysis
PROPARK year 2
(70 pt missing values) 
pt stereotactical surgery
344 pt in cluster
analysis
PROPARK year 1
(53 pt missing values)
387 pt ELEP - cohort
23 pt stereotactical surgery
357 pt in cluster
analysis
ELEP
(7 pt missing values)
Figure 1. Flow chart of patients. 
pt: patients
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N 344 276 357
Sex, men/women (% men) 226/118 (66%) 184/92 (67%) 193/ 164 (54%)
Disease duration, yrs, mean (SD) 9.9 (6.2) 11.0 (6.2) 7.7 (5.8)
Age, yrs, mean (SD) 60.8 (11.3) 61.5 (11.0) 66.2 (11.2)
Age at onset, yrs, mean (SD) 50.8 (11.9) 50.5 (11.8) 58.5 (11.7)
H&Y, median (IQR) 2 (2-3) 3 (2-4) 2 (1-2)
Patients on L-dopa, N (%) 223 (65%) 199 (72%) 267 (75%)
Patients on DA, N (%) 234 (68%) 192 (70%) 242 (68%)
H&Y; Hoehn and Yahr stage, IQR; interquartile range, L-dopa; levodopa, DA; Dopamine agonists
Cluster characteristics
The VVI-5 model was optimal according to the BIC table (Table 2). However, the EII-4 model (<5% 
lower than the optimal BIC score) was selected based on the additional criteria: 
1. The 4-cluster solutions showed more stability than the 5-cluster solutions, since they exhibited 
larger agreement between different models: Cramer’s V: 4-cluster solutions range 0.462-0.909; 
5-cluster solutions range 0.488-0.655; agreement between EII-3 and EII-4 0.832; agreement 
between EII-4 and EII-5 0.925. 
2. The EII-4 model showed good reproducibility in data of year 2: Agreement in cluster allocation 
year 1 and 2: 65% for the total group, and 87% for patients with a ≥95% cluster probability. 
3. The EII model is the simplest model. 
4. The sizes of the 4 clusters of the EII-4 model were all >5% of the total sample size. 
Table 2. BIC table of the model based cluster analysis on data of PROPARK year 1. 
Number of clusters EII VII EEI VEI VVI
3 4.37 3.05 4.40 2.98 1.19
4 4.21 2.74 4.18 2.76 0.18
5 4.12 2.90 4.05 2.55 0.00
BIC results for different models with increasing complexity. The complexity of the models increases 
downwards (larger number of clusters) and from left to right (models increasing in complexity, i.e. 
a larger number of parameters is estimated). The BIC values of the other models are expressed in 
percentages lower than the optimal one. The model with the BIC value of 0 is the optimal one, which 
is the VVI model for 5 clusters in this data set. 
Cluster 1 (49%) was characterized by an overall mild severity in all clinical domains. These patients 
were relatively young, had a younger AO and had lower intake of and shorter exposure to L-dopa. 
Cluster 2 (13%) was characterized by severe and frequent MCs, and moderately severe sleep 
problems and depressive symptoms. These patients had longer disease duration and higher intake 
of and longer exposure to dopaminergic medication than patients in other subtypes. Patients in this 
subtype were comparatively young and had the youngest AO, and the proportion of women was 
relatively large.
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Figure 2 a – c. Heatmaps of the EII – 4 models. 
A: PROPARK cohort year 1, B: PROPARK cohort year 2, C: ELEP cohort 
Foss: an axial motor factor consisting of ‘freezing during on’, ‘swallowing’, ‘speech’. Pigd: an 
axial motor factor consisting of ‘rise’, ‘gait’ and ‘postural instability’.
Each column represents a cluster. The colors indicate whether the cluster mean severity of a 
symptom is lower (blue color) or higher (red color) than the mean of the total group.
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Cluster 3 (30%) showed intermediate severity in nondopaminergic domains, while MCs were mild 
and less frequent. Patients were relatively old and had a higher AO.
Cluster 4 (8%) included patients who were severely affected in most domains, although tremor was 
relatively mild. MCs were prominent but less severe than in Cluster 2. This cluster was characterized 
by relatively high age and AO, long duration of L-dopa use, and a comparatively large proportion 
of women. 
Disease duration did not significantly differ between Clusters 1, 3, and 4.
See figure 2A, tables 3 and 4.
Table 3: Cluster characteristics of the four clusters of PROPARK cohort year 1. 
Symptoms (range scores) Cluster 1 Cluster 2 Cluster 3 Cluster 4
N (%) 169 (49%) 45 (13%) 104 (30%) 26 (8%)
Bradykinesia/rigidity (0-12) 4.7 (1.7) 2,3,4 3.8 (1.7) 1,3,4 5.5 (1.8) 1,2,4 7.4 (2.0) 1,2,3
Tremor (0-12) 3.6 (1.9) 3.1 (1.8) 3 4.1 (2.2) 2 3.1 (1.5)
PIGD ( 0-9) 1.2 (1.1) 2,3,4 2.2 (1.5) 1,3,4 3.1 (1.7) 1,2,4 4.8 (1.8) 1,2,3
Cognitive impairment (0-43) 14.7 (5.5) 3,4 15.8 (4.8) 3,4 19.7 (5.4) 1,2,4 25.7 (5.1) 1,2,3
Psychotic symptoms (0-15) 1.0 (1.1) 2,3,4 2.4 (1.7) 1,4 2.3 (1.7) 1,4 4.8 (2.0) 1,2,3
Autonomic dysfunction (0-36) 7.1 (4.1) 2,3,4 11.3 (4.4) 1,3,4 13.5 (5.1) 1,2 15.7 (6.1) 1,2
Daytime sleepiness (0-18) 2.9 (2.6) 2,3,4 4.4 (3.9) 1,3 7.7 (3.5) 1,2 6.4 (3.0) 1
Depression (0-63) 6.7 (4.0) 2,3,4 13.9 (5.5) 1,3,4 10.6 (4.9) 1,2,4 21.5 (8.3) 1,2,3
Nighttime sleep problems (0-15) 3.1 (3.1) 2,3,4 7.7 (3.0) 1,3 4.5 (3.8)  1,2,4 7.0 (3.6) 1,3
Motor fluctuations (0-6) 0.3 (0.8) 2,4 2.8 (1.2) 1,3,4 0.4 (0.9) 2,4 1.2 (1.5) 1,2,3
Dyskinesias (0-6) 0.5 (1.3) 2,4 2.3 (1.9) 1,3 0.4 (1.2) 2,4 1.8 (1.8) 1,3
FOSS (0-9) 1.5 (1.2) 2,3,4 3.0 (1.9) 1,4 2.6 (1.6) 1,4 4.2 (1.5) 1,2,3
Means (SD) presented for all variables. For all PD signs and symptoms: higher scores reflect more 
problems.
In the columns presenting data of Clusters 1-4 only significant differences are indicated:
1) Significant difference (P< 0.05) with Cluster 1 (ANOVA)
2) Significant difference (P< 0.05) with Cluster 2 (ANOVA)
3) Significant difference (P< 0.05) with Cluster 3 (ANOVA)
4) Significant difference (P< 0.05) with Cluster 4 (ANOVA)
PIGD; rise, gait, postural instability, FOSS; freezing, speech, swallowing.
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Table 4. Cluster characteristics on variables that were not included in the cluster analysis 
(PROPARK cohort year 1). 
Cluster 1 Cluster 2 Cluster 3 Cluster 4
Disease duration, yrs a 9.1 (6.3) 2 12.3 (5.3) 1 10.3 (6.4) 9.9 (4.6)
Age, yrs a 57.8 (10.6) 3,4 57.8 (9.6) 3 65.9 (10.3) 1,2 64.7 (14.2) 1
Age onset, yrs a 48.7 (11.5) 3 45.4 (9.3) 3,4 55.6 (10.8) 1,2 54.9 (14.3) 2
Sex, m/w (% men) b 119/50 (70) 2 22/23 (49) 1 73/31 (70) 12/14 (46) 
1st and 2nd degree relatives 
with PD, N (%) b
42 (25) 13 (29) 22 (21) 5 (19)
















H&Y, median (IQR) b 2 (2-2) 2,3,4 3 (2-3) 1,4 3 (2-3) 1,4 4 (3-4)1,2,3
Presence of motor fluctuations, % yes b 14 2,4 96 1,3,4 19 2 42 1,2
Presence of dyskinesias, % yes b 14 2,4 69 1,3 14 2,4 53 1,3
LDE, mg a 436 (379) 2 989 (556) 1,3,4 570 (375) 2 606 (394) 2
LDE L-dopa, mg a 230 (283) 2,3,4 585 (403) 1,3 377 (334) 1,2 432 (323) 1
LDE DA, mg a 205 (226) 2 405 (247) 1,3,4 193 (191) 2 173 (210) 2
Exposure to L-dopa, yrs a 2.7 (4.2) 2,3,4 7.3 (5.2) 1,3 4.9 (5.3) 1,2 7.5 (4.6) 1
Exposure to DA, yrs a 2.7 (3.2) 2 5.4 (3.2) 1,3 3.5 (3.9) 2 4.2 (3.9)
Patients on clozapine, N (%) b 4 (2) 3 (7) 3 (3) 3 (12)
Patients on amantadine, N (%) b 46 (27) 4 17 (38) 42 (40) 15 (58) 1
Means (SD) presented for all variables unless stated otherwise.
a) ANOVA, post – hoc t – test with Bonferroni correction for multiple testing
b) Chi square test, Bonferroni correction for multiple testing
c) Kruskal-Wallis
In the columns presenting data of Clusters 1-4 only significant differences are indicated:
1) Significant difference (P< 0.05) with Cluster 1 
2) Significant difference (P< 0.05) with Cluster 2 
3) Significant difference (P< 0.05) with Cluster 3 
4) Significant difference (P< 0.05) with Cluster 4 
H&Y; Hoehn and Yahr stage, IQR; interquartile range, LDE; levodopa dose equivalent, L-dopa; levodopa, 
DA; dopamine agonists.
The discriminant analysis showed that motor fluctuations, PIGD, and depression best discriminated 
the four subtypes of the PROPARK cohort. Based on those variables 251 (73%) patients were correctly 
classified. Of the demographic- and disease-related variables, AO and total LDE best discriminated 
the four subtypes; based on these variables 170 (50%) patients were correctly classified. When AO 
was substituted by age, 167 (49%) patients were correctly classified.
Opmaak 2.indd   77 21-09-12   15:32
78  | Clinical subtypes of Parkinson’s disease
Cluster validation
The EII-4 model of the ELEP cohort was similar to the one obtained in the PROPARK cohort (Figure 
2c). Clusters 1-4 comprised 58%, 11%, 27% and 5% of the patients, respectively. This distribution 
did not significantly differ from the distribution of the PROPARK subtypes (χ2=6.21; df=3; P=0.102). 
Discriminant analysis showed that motor fluctuations, PIGD, and autonomic dysfunction correctly 
classified 286 (80%) patients in the ELEP cohort. Using the same discriminative variables as in the 
PROPARK cohort (depression instead of autonomic dysfunction), 274 (77%) patients were correctly 
classified. 
Discussion
Conspicuous clinical heterogeneity exists among PD patients, which is most likely attributable to 
differences in the mechanisms that underlie PD and complications of dopaminergic treatment. In 
this study we aimed to identify clinical subtypes in PD and found four subtypes. The strengths of 
this study are the use of a data-driven approach in a large number of patients who were extensively 
characterized on a broad array of motor and nonmotor domains. Moreover, the results were 
validated in an independent Spanish cohort, in which patients were assessed by similar measurement 
instruments as in the PROPARK cohort. The latter finding emphasizes the transcultural validity of 
these subtypes and underscores their robustness in spite of differences in sample collection and 
sample characteristics. 
By comparing the profiles of the subtypes (Figure 2) it appeared that two subtypes (Clusters 1 and 
4) differed only by a severity gradient (benign versus malignant), regardless the clinical domain 
of interest. However, the profile of the other subtypes (Clusters 2 and 3) showed that, based on 
severity, certain clinical domains grouped together. This grouping of clinical domains is consistent 
with the results from an earlier study on the coherency of motor and nonmotor domains.7 Two 
subtypes (Clusters 3 and 4) had prominent involvement of PIGD, cognitive impairment, autonomic 
dysfunction, psychosis, daytime sleepiness, and depression; predominantly nondopaminergic 
features (PND complex). In our previous study this PND complex was associated with both disease 
severity and age and most likely reflects advancing disease.7 PIGD has been previously identified as 
an important motor phenotype associated with cognitive decline, a higher risk for depression, and 
a more progressive course.14-18 When PD is viewed from a broader perspective, PIGD may actually be 
the motor component of the much larger PND complex.
A tremor dominant subtype associated with a more favorable disease course14-16 was not identified 
in this study. Recently, a clinicopathologic study showed that tremor is not an independent indicator 
of a benign disease course.19 In addition, a longitudinal study showed that with the development 
of PIGD, the number of tremor pre-dominant patients gradually decreased.17 Hence, the prevalent 
character of both cohorts used in this study (mean disease durations 10 and 8 years), may explain 
why a tremor dominant subtype was not identified. 
The two subtypes with prominent involvement of the PND complex (Clusters 3 and 4) had higher AO 
and age than the two other subtypes (Clusters 1 and 2). Because of the cross-sectional nature of this 
study and largely similar mean disease duration of the subtypes, it is impossible to unravel whether 
AO or age most strongly determined disease severity. In the previous CA studies, cluster profiles 
were characterized on higher AO and rapid disease progression.3 However, in longitudinal studies 
on cognitive impairment in PD where both AO and age were taken into account, only the latter was 
found related to faster rate of cognitive decline.20,21 Compelling data from other studies suggest 
that advancing age is also an important determinant of clinical progression in PD, as reflected by 
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PIGD, cognitive decline, and hallucinations.19,22 Notably, clusters with a similar AO and age also 
showed remarkable differences in severity of the PND complex (Clusters 1 versus 2 and 3 versus 
4); underscoring that in addition to aging, other disease-modifying factors must play a role in the 
progression of PD. Levy proposed an appealing model in which nondopaminergic manifestations 
result from biologic interaction between the disease process and aging.20 The PND complex likely 
reflects advancing Lewy body pathology,23 which has been related to the enhanced level of alpha-
synuclein.24 Interestingly, the latter is influenced by both the disease process and aging.25 Aging may 
influence the progression of PD through shared involvement of processes fundamental to neuronal 
vitality, including the maintenance of protein homeostasis and mitochondrial function.26
Our results further identified two subtypes with pronounced MCs (Clusters 2 and 4). Young AO, 
female gender, higher (cumulative) L-dopa dose, longer duration and higher severity of the disease 
have been reported risk factors for MCs.27-29 Except for disease severity, all reported determinants 
were identified in Cluster 2. Conversely, in Cluster 4, only female gender and disease severity were 
identified determinants. Because younger AO is considered a risk factor for development of MCs 27,30 
it was surprising that also a substantial number of patients with an older AO clustered in a subtype 
with pronounced MCs. The finding that female gender was the only common risk factor in both 
subtypes with MCs highlights that subtype-specific interactions between medication and disease 
related variables may result in a certain susceptibility to MCs. Subtypes with prominent MCs also 
exhibited more severe mood and sleep disturbances. MCs may directly affect sleep and mood, but 
clustering of these symptoms may also be linked by factors related to female gender, since insomnia 
and depression are more frequent in women.31 
In conclusion, PD subtypes are largely characterized by the severity on two axes: the PND complex 
and MCs. Axial function and MCs, derivatives of both axes, discriminated best between subtypes, 
providing further support for this classification. Our findings further show that subtype expression 
is based on complex interactions between disease mechanisms, treatment, aging, and gender. 
These findings may have consequences for epidemiologic studies and trials, which hitherto have 
considered PD a homogeneous disorder, since risk factors and treatment effects may be subtype-
specific. The contribution of genetic factors in the subtypes was not evaluated, since a previous 
screening for mutations in the Parkin, DJ-1, PINK1, LRRK2, and SNCA gene in the PROPARK showed 
that pathogenic variations were demonstrated in only 4% of the patients.32 Hence, it seems unlikely 
that differences between clusters can be explained by these known mutations. 
With the model-based CA, we have tried to avoid the disadvantages of hierarchical and k-means CA. 
In contrast to these methods, model-based CA is not sensitive to outliers and the model and number 
of clusters is not arbitrarily chosen but guided by a fit statistic.11,33,34 This method estimates different 
models, varying in assumptions on the distribution of the clusters, thereby resulting in more precise 
solutions.11,34 And, more importantly, we were able to validate the results in an independent sample.
The recruitment strategy of PROPARK, aimed at obtaining an equal distribution of AO and disease 
duration, may limit generalization of our findings. However, this study aimed to identify subtypes and 
not their prevalence. Furthermore, despite different sample characteristics of the ELEP cohort, we 
identified similar subtypes. Because disease duration may influence the phenotypic expression of the 
disease, we aimed to correct each variable for the influence of disease duration. Small differences in 
mean disease duration between the subtypes nevertheless remained (range, 9.1-12.3 years), which 
was significant only between Clusters 1 and 2. Thus, it seems unlikely that these differences play 
a decisive role in the differential expression of subtypes. Nevertheless, the cross-sectional design 
of the study precludes the possibility to determine whether patients within clusters had followed 
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similar disease courses. Moreover, given the prevalent nature of both cohorts, it is impossible 
to determine which factors at disease onset predict the subsequent development into particular 
subtypes. Collectively, this knowledge could be important for the development of tailored treatment 
strategies, and, also, highlights the need for longitudinal studies on incident cases. 
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Summary 
The clinical heterogeneity of Parkinson’s disease (PD) patients may reflect the existence of subtypes of 
the disease. PD subtypes have often been defined by a classification according to researcher-specified 
criteria, such as age-at-onset or predominant clinical motor features. The general objective of this 
thesis was to identify and characterize clinical subtypes in PD by a data-driven approach, based on a 
comprehensive assessment of all relevant PD domains. In order to obtain insight in the associations 
and coherence of impairments that are involved in the disease, we evaluated the contributions of 
impairment and disability domains to health-related quality of life in patients with PD. Subsequently, 
the data of the PROPARK cohort was used to study coherency patterns within the motor domain and 
in the spectrum of motor and nonmotor domains. In our study on subtypes, first, we systematically 
evaluated the results of earlier studies that performed cluster analysis (CA) to identify subtypes in 
PD, after which we applied CA on data of the PROPARK cohort in order to identify subtypes of the 
disease. In this final chapter, the results are summarized and discussed and possible directions for 
future research are suggested.  
We systematically reviewed the methodology and results of CA studies in PD to gain a better 
understanding of the robustness of identified subtypes in chapter 2. Seven studies fulfilled the 
inclusion criteria. The cluster profiles ‘old age-at-onset (AO) and rapid disease progression’ and ‘young 
AO and slow disease progression’ emerged from the majority of studies. Other cluster profiles were less 
consistent across studies. However, studies were limited by incomplete reporting and methodological 
shortcomings and differences between studies in methodology rendered comparisons of the results 
difficult. Studies which applied a comparable design identified similar subtypes, supporting the 
importance of a standardized approach in CA studies. Since CA studies with a rigorous, standardized 
design may increase our knowledge on subtypes, we made recommendations for future studies with 
respect to the sample, the included variables, data processing, and CA technique.  
In chapter 3, the aim was to create insight in how impairments and disabilities related to PD influence 
health related quality of life (HRQoL) of these patients. This insight is an important prerequisite to 
evaluate the adequacy of current management strategies. Impairments and disabilities were assessed 
in 378 PD patients from the SCOPA/PROPARK cohort. HRQoL was assessed with the EuroQol-5D Visual 
Analogue Scale. Using multiple linear regression analysis and structural equation modelling a model 
of factors that influence HRQoL with a good fit could be constructed. Of the disabilities, psychosocial 
well-being had a larger impact on HRQoL than physical functioning. Of the impairments, depression 
had the largest contribution to HRQoL, followed by axial motor symptoms, gastrointestinal symptoms, 
and urinary symptoms. In addition, pain, psychiatric and motor complications, and daytime sleepiness 
had small but significant influences on HRQoL. It can thus be concluded that in PD patients HRQoL is 
affected by multiple factors, including disabilities, nonmotor domains and axial symptoms. It should 
be realized that in patients who are on dopaminergic treatment, intended to alleviate mainly motor 
symptoms, there is a large impact of nonmotor and nondopaminergic symptoms on HRQoL. Research 
is warranted for management strategies with a multidisciplinary approach for these aspects of the 
disease that impact on HRQoL. 
The goal of chapter 4 was to identify patterns of motor disturbances in PD and evaluate their 
relation with other PD domains. For this purpose, a cohort of 399 PD patients was randomly divided 
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into two samples. On data of the first sample, an exploratory factor analysis was performed to 
identify factors in the items of the motor evaluation section of the SPES/SCOPA. These factors were 
next evaluated by confirmatory factor analysis in the second sample. Subsequently, relations with 
other PD domains were evaluated by regression analyses. A four factor model was found to be valid. 
This included a tremor, a bradykinetic-rigid, and two axial factors. One axial factor (containing the 
items “rise”, “gait”, “postural instability”) was associated with age and cognition, while the other 
axial factor (containing the items “freezing”, “speech”, “swallowing”) was related to dopaminergic 
medication and complications of therapy. Both other factors showed no relevant associations with 
demographic and clinical characteristics. It was concluded that the motor disturbances in PD could 
be classified into four factors. It is expected that different mechanisms underlie the different factors. 
The identification of motor factors and their relation with other domains of the disease may help to 
elucidate the mechanisms responsible for these associations. Furthermore, these factors provide an 
objective base for further research on subtypes in PD. 
In chapter 5 the presence and nature of patterns of coherency among the motor and nonmotor 
domains in PD was evaluated, as well as their relation with disease severity, disease duration, and 
dopaminergic therapy. A cohort of 397 PD patients was randomly divided into two samples. In the 
first sample, exploratory factor analysis (EFA) was performed on the motor and nonmotor symptoms 
in PD. Findings of the EFA were used to construct a model which was tested in the second sample 
by confirmatory factor analysis. Multiple regression analyses were performed on the resulting factors 
to evaluate the influence of clinical parameters upon these factors. Four factors were identified. 
The first and strongest factor (consisting of cognitive impairment, autonomic dysfunction, psychotic 
symptoms, depression, daytime sleepiness, and axial symptoms) was related to disease severity. 
Another factor largely reflected motor complications of therapy and was related to dopaminergic 
medication. The other two factors, consisting of sleep/depression and tremor/bradykinesia/rigidity, 
were only marginally related to disease severity or medication. Our findings show that the motor and 
nonmotor features in PD can be characterized by four distinct patterns of coherency, which provide 
insight in the contributions of the primary disease process and anti-parkinsonian medication to the 
broad clinical spectrum of PD. One factor, consisting of predominantly nonmotor symptoms together 
with axial symptoms, clearly reflected advancing disease and may provide a new basis for monitoring 
disease progression in PD.
Since the clinical heterogeneity in PD may point at the existence of subtypes, the objective of 
chapter 6 was to identify PD subtypes by a data-driven approach based on a broad spectrum of 
motor and nonmotor features. We collected data of motor and nonmotor PD features in 802 patients 
in two different European prevalent cohorts. A model based CA was conducted on baseline data 
of 344 patients of a Dutch cohort (PROPARK). Reproducibility of these results was tested in data 
of the 2nd annual assessment of the same cohort, and validated in an independent Spanish cohort 
(ELEP) of 357 patients. The subtypes were subsequently characterized on clinical and demographic 
variables. Discriminant analysis was performed to determine which variables best discriminated the 
subtypes. Four similar PD subtypes were identified in two different populations: Patients in subtype 
1 were mildly affected on all domains, subtype 2 was predominantly characterized by severe motor 
complications but only mildly affected on nondopaminergic symptoms, subtype 3 was mainly 
characterized by affected nondopaminergic symptoms without prominent motor complications, 
while patients in subtype 4 were severely affected on all domains. Post-hoc analyses showed that 
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the subtypes had largely similar disease duration, but clearly differed in age, AO, dopaminergic 
treatment and gender. We concluded that PD subtypes in prevalent disease are largely characterized 
by the severity of nondopaminergic features and motor complications. Complex interactions between 
disease mechanisms, treatment, ageing, and gender likely underlie these subtypes. 
Concluding remarks
There is an increasing awareness of the potential importance of the identification of subtypes in 
PD because of the consequences for both our insight in underlying disease mechanisms and the 
development of tailored treatment strategies. Several studies aimed to identify subtypes in PD by 
CA, which is an objective method to group patients with similar phenotypes. Hitherto, studies 
that performed CA on the broad spectrum of PD features showed methodological limitations and 
variations in design rendered comparisons difficult. Recommendations were made regarding the 
methodology for future studies applying CA, which were followed optimally in the CA that was 
performed in this thesis. Identification of subtypes based solely on measures reflecting motor and 
nonmotor features of PD and not on demographic, medication or progression-related variables 
provide the opportunity to obtain conceptually clear solutions. When a classification is based on 
different levels like symptoms at onset, and age of disease onset, and rate of disease progression 
simultaneously (e.g. tremor dominant, early onset, rapid disease progression), patients may not 
exclusively belong to one subtype: Selikhova et al. demonstrated that patients, who were allocated 
to the subtype ‘rapid disease progression’ in a four-group classification, were mainly included in the 
‘tremor-dominant’ and to a lesser extent in the ‘non-tremor dominant subtype’ in the three-group 
classification.1 
Robust data-driven analysis (factor- and cluster analysis) on the broad array of clinical features 
resulted in the detection of distinct coherency patterns of impairments, as well as unique subtypes. 
Interestingly, coherency patterns of impairment domains which were revealed by the factor analysis, 
were also identified in the profiles characterizing subtypes of the disease. Four subtypes could be 
identified that were largely characterized by the severity of two important factor components, 
namely the PND complex (predominantly nondopaminergic symptoms; PIGD, cognitive impairment, 
autonomic dysfunction, psychosis, daytime sleepiness, and depression) and motor complications: 
across the four subtypes, the severity of the PND complex increased. Additionally, two subtypes 
were characterized by severe motor complications Patients in the four subtypes had largely similar 
disease duration, but showed considerable differences with respect to their association with age, AO, 
dopaminergic treatment, and gender. Likely, complex interactions between these features as well as 
genetic predisposition, compensatory mechanisms, and disease mechanisms, determine a subtype-
specific susceptibility to the PND complex and motor complications, and thereby the phenotypic 
expression.2-4 Thus, although the term ‘Parkinson’s disease’ seems to imply a homogeneous entity, 
many studies, including studies presented in this thesis, show that PD should not be regarded as 
a homogeneous disorder.5 Further, characterizing subtypes on the basis of one feature, e.g. PIGD-
dominant, likely reduces the yield in studying subtypes since our results show that two axes (PND 
complex and motor complications) provide a better characterisation of the different subtypes. 
Additionally, classifying patients on a single clinical parameter, e.g. AO, would probably be too 
simplistic, since interactions between clinical parameters may determine the clinical expression on 
both axes and thereby the subtype.
Since the PND complex was associated with age and motor disease severity (as measured by Hoehn 
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and Yahr [H&Y] stage), this coherence pattern was considered to be key in characterizing the disease 
process. With a comprehensive model to study the impact of each of the motor and nonmotor 
impairments and disabilities on HRQoL it was shown that depression, axial symptoms, and autonomic 
dysfunction were the most important determinants of HRQoL. Interestingly, all three features are part 
of the PND complex. Further, subtypes could be well discriminated by axial symptoms and depression, 
in combination with motor fluctuations. Collectively, these findings underscore the relevance of 
these domains in the clinical practice. Notably, the classical PD features tremor, bradykinesia, and 
rigidity did not emerge as important determinants from any of these analyses. However, the effect of 
these symptoms may be masked by the dopaminergic replacement therapy. 
Implications and future directions
Subtypes
The study on subtypes in PD is still in its infancy.6 Firstly, the results of this thesis require confirmation 
in other cohorts. Since the publication of our studies, two other studies applying CA in order to 
identify subtypes have been published.7,8 However, both studies have included different kinds of 
variables (PD signs and symptoms, demographic variables, measures of disease progression) in their 
analyses. Consequently the results of those studies cannot be compared with those of our study. 
Secondly, patients in the subtypes in our study had similar mean disease duration and thus it is likely 
that differences between subtypes reflect differences in progression of the disease. However, given 
that the results on subtypes in this thesis are derived from a cross-sectional study, it remains unclear 
if subtypes are also characterized by specific longitudinal patterns of change. An incident cohort 
with long-term follow-up may provide insight in differences between subtypes in progression and 
in determinants at baseline that predict subsequent development into a particular subtype. Thirdly, 
the results of this thesis need to be validated by objective markers. Biomarkers are measurable 
components along the pathway between disease and its underlying biological pathophysiology. With 
the identification of biomarkers mechanisms underlying the subtypes may be elucidated. Moreover, 
biomarkers have the potential to identify persons at-risk before overt expression of the disorder.
The nature of PD is complex and multiple factors may contribute to the development of different 
subtypes. Further research on these factors needs to be aimed at many areas. Two main directions will 
be discussed below. Finally, implications of the results of this thesis for treatment will be discussed. 
Ageing 
Our results indicated clear differences between subtypes in age at onset and age. In view of the 
cross-sectional nature of our cohort it is not possible to determine whether age at onset or age 
is the key in the expression of the subtype. An important role for age specifically with respect 
to the nondopaminergic symptoms has also been suggested in other studies.9-11 In parallel, more 
fundamental studies also highlighted the importance of age in the pathologic mechanisms in PD. 
Neurodegenerative diseases like synucleinopathies and tauopathies do not clinically present until a 
certain age has been achieved, suggesting a role for the ageing process in the development of these 
diseases or common mechanisms of ageing and neurodegeneration.12 Additionally, PD and Alzheimer’s 
disease show an overlap in pathological processes and genetic features.13-16 However, in our study, 
subtypes characterized by similar age and AO also showed differences in disease severity. Similarly, 
other studies showed that differences between subgroups in disease severity or higher cortical Lewy 
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body scores could not be explained by age.1,11 In various studies, hallucinations, cognitive disability, 
regular falls, and need for residential care occurred at a similar time to death, irrespective of age, 
AO or disease duration.10,17,18 This indicates that the occurrence of these symptoms, rather than 
age, reflects the pathological endpoint. Kempster et al. suggested that age influences the disease 
in the early and middle part of the disease, but not in the end stage.10,17,18 A study on predictors 
of Alzheimer’s disease showed that ageing, defined as ‘age associated decline in health status’ as 
reflected by a frailty index, appeared as a risk factor, in addition to age.19,20 Age is an indicator for, but 
not identical to ageing; ‘while some 70-year old persons need residential care, other 70-years olds 
still go hiking in the mountains’. The patients who were evaluated on their clinical presentation in the 
years prior to death,10,17,18 were likely in a similar stage of cellular ageing and neurodegeneration, but 
with a variable age. Considering this possibility, ageing may thus influence the disease at all stages. 
Obviously, these are hypotheses that require confirmation.
Recent studies suggested that cellular ageing and misfolding of the alphasynuclein protein are 
influenced by common genetic pathways, indicating an important relationship between the genetics 
of ageing and PD. 21,22 Also genetic pathways are identified that are related to ageing and PD, but 
with an increased expression level in PD, and genetic pathways were identified that are specific 
for PD.23 A better understanding of processes that occur during “normal ageing”, with respect to 
imbalance in protein homeostasis in the cells, and in the brain during the disease course of PD may 
have consequences for both our understanding of mechanisms of disease and the development of 
new therapeutic targets.24 
Neural plasticity
Given the observations that large numbers of neurons in the substantia nigra die before clinical 
features emerge in PD patients and that some subjects have substantial amounts of alphasynulein 
pathology in the central nervous system without clinical manifestations, it is suggested that 
pathologic processes can be modulated by compensatory mechanisms. Through compensatory 
mechanisms or neural plasticity, the brain may adapt to neuronal loss, thereby maintaining neuronal 
functions.4,15 However, plasticity is also known to induce negative effects: aberrant neural plasticity 
may be responsible for the development of dyskinesias.25,26 Thus, differences in the expression of 
plasticity may explain differences between subtypes in the severity on both axes, namely disease 
severity as reflected by the PND complex and the severity of motor complications. The expression of 
plasticity is determined by genetic mechanisms which are also under the control of age and it may 
further be modulated by denervation and dopaminergic medication.25,26 Recently, a polymorphism 
of the brain derived neurotrophic factor (BDNF) gene, which plays a role in modulating synaptic 
plasticity, appeared to be related to time to onset of dyskinesias.27 Also, variations in the Catechol-
O-methyltransferase (COMT) gene have been found related to increased susceptibility to the 
development of dyskinesias.28 Further research on these and other polymorphisms, may provide 
insight in the underlying mechanisms of the subtypes and polymorphisms may eventually serve as 
predictors for the development into a particular subtype.
Treatment
In the PROPARK cohort the nondopaminergic symptoms appeared to have a large impact on disease 
severity, subtype characterisation, and HRQoL in patients with PD. However, these findings should 
be interpreted against the background of a cohort that is characterized by longstanding disease and 
use of dopaminergic medication, which reduces the severity of some typical motor features of the 
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disease and may have biased our findings. From data of an longitudinal incident cohort it appeared 
that a ‘dopa-resistant subscore’ including speech, posture, gait, postural instability, and rising from 
sitting, predicted more rapid progression to H&Y 3, and this dopa-resistant subscore appeared as an 
index of progression that was more sensitive than both the UPDRS 2 (section activities of daily living) 
and 3 (section motor examination), thus supporting our results.29 These findings point out the need 
for better management strategies for the nondopaminergic symptoms, which now seems to be the 
greatest challenge.30,31 
Since current available therapies cannot control these nondopaminergic features, neuroprotective 
or disease modifying therapies are being developed which aim at prevention or delay of the 
disease progression. However, hitherto no agent has given proof of a neuroprotective effect yet.32-
34 One of the issues that may influence the results of a trial testing an intervention with assumed 
neuroprotective action is the selection of a suitable outcome measure. Outcome measures that 
have been selected in previous trials included the slope of the UPDRS score and time to levodopa 
therapy, shift to H&Y stage III, or the development of motor complications.32,34 Results in this thesis 
show that the spectrum of PD signs and symptoms consists of four different patterns of coherency, 
each of them associated with different characteristics. Information on the severity of at least two 
out of these coherency patterns is required to discriminate subtypes. Hence, in trials important 
information may be missed when a single primary outcome measure is selected: a positive effect 
on one outcome measure may coincide with a negative or no effect on another outcome measure. 
Alternatively, application of the Global Statistical Test methodology allows for a selection of several 
relevant outcomes in the evaluation of a treatment effect.35 A second point, relevant not only for 
these trials but for all research in PD, relates to the notion that by regarding PD as homogeneous 
disease, subtype-specific risk factors or treatment effects may be missed. Hence, identification of 
determinants, ideally objective biomarkers, which predict a disease course of a particular subtype, 
is of great importance for disease management: In trials patients can be stratified, so that subtype-
specific effects can be evaluated. Moreover, the effectiveness of therapy might be greatly improved 
when patient-specific treatment strategies can be applied. 36
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94  | List of abbreviations
χ2 Chi-square
ADL Activities of daily life/ Activities of daily living
AO Age-at-onset
ANOVA Analysis of variance
BDI Beck Depression Inventory
BDNF Brain derived neurotrophic factors
BIC Bayesian Information Criterion
CA Cluster analysis
CFA Confirmatory factor analysis/ Confirmatieve factor analyse




Df Degrees of freedom
DS  Daytime sleepiness
Dysk Dyskinesias
EFA Exploratory factor analysis/ Exploratieve factor analyse
ELEP Estudio Longitudinal de pacientes con Enfermedad de Parkinson
EQ-5D EuroQol five dimension 
EQ-VAS EuroQol Visual Analogue Scale
Et al. Et alii (and others)
Fig Figure
FOSS A factor comprising Freezing during on, Swallowing, and Speech
GBA Glucoserebrosidase
GI Gastrointestinal
H&Y Hoehn and Yahr
HADS Hospital Anxiety and Depression Scale
HRQoL Health related quality of life
I.e. Id est (that is)
IQR Interquartile range
JM Johan Marinus
LDE Levodopa dose equivalent
L-dopa Levodopa
LRRK2 Leucine rich repeat kinase 2
LUMC Leiden University Medical Centre
M Men
MC  Motor complications
ME Motor Evaluation
MF  Motor fluctuations
Mg Milligram
MMSE Mini Mental State Examination
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MS Motor symptoms
NSAID Non-Steroidal Anti-Inflammatory Drug
NFI Normed Fit Index
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NNFI Nonnormed Fit Index
NS Nighttime sleep problems
NS  Not specified
PBF Prinses Beatrix Fonds
PD Parkinson’s disease
PDQ-39 Parkinson’s Disease Questionnaire – 39 item version
PIGD Postural instability and gait difficulty
PINK1 PTEN-induced kinase 1
PM Pupillomotor
PND Predominantly Nondopaminergic features
PPRS Parkinson psychosis rating scale
Prof. Professor
PROPARK PROfiling PARKinson’s disease
Pt Patients
QoL Quality of life
REM Rapid eye movement
RMSEA Root means square error of approximation
SCOPA Scales for Outcomes in PArkinson’s disease
SCOPA-AUT SCales for Outcomes in PArkinson’s disease – AUTonomic function
SCOPA-COG SCales for Outcomes in PArkinson’s disease – COGnition
SCOPA-PC SCales for Outcomes in PArkinson’s disease – Psychiatric 
Complications
SCOPA-PS SCales for Outcomes in PArkinson’s disease –PsychoSocial
SD Standard deviation
SEM Structural Equation Modeling
SPES Short Parkinson Evaluation Scale
SPES/SCOPA Short Parkinson Evaluation Scale/ SCales for Outcomes in PArkinson’s 
disease
SPES/SCOPA-ADL Short Parkinson Evaluation Scale/ SCales for Outcomes in PArkinson’s 
disease – activities of daily living
SPES/SCOPA-MC Short Parkinson Evaluation Scale/ SCales for Outcomes in PArkinson’s 
disease – motor complications
SPES/SCOPA-MS Short Parkinson Evaluation Scale/ SCales for Outcomes in PArkinson’s 
disease – motor symptoms
SPSS Statistical Package for Social Sciences
SR Stephanie van Rooden
SRMR Standardized root mean square residual
SX Sexual dysfunction 
TR Thermoregulatory
UK United Kingdom
UPDRS Unified Parkinson’s Disease Rating Scale
UR Urinary
VAS Visual Analogue Scale
W Women
Yrs Years
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Na de ziekte van Alzheimer is de ziekte van Parkinson de meest voorkomende neurodegeneratieve 
aandoening. De ziekte wordt gekenmerkt door traagheid van bewegen (bradykinesie), beven (tremor), 
stijfheid (rigiditeit) en instabiliteit. Dit zijn de zogenaamde motorische kenmerken. Daarnaast 
is er nog een aantal kenmerken dat geen betrekking heeft op het bewegen, de non-motorische 
kenmerken. Dit zijn onder andere reukstoornis, problemen met het denkvermogen, slaapproblemen, 
slaperigheid overdag, depressieve symptomen, hallucinaties en zogenaamde autonome problemen, 
waaronder problemen met de spijsvertering, de bloedsomloop, het plassen en seksualiteit. Daarnaast 
kunnen patiënten als gevolg van de medicatie last krijgen van overbeweeglijkheid (dyskinesieën) en 
het plotseling niet werken van de medicijnen (motorische fluctuaties). Patiënten kunnen worden 
behandeld met levodopa, maar dit heeft alleen effect op de motorische problemen. Hoe de ziekte 
van Parkinson ontstaat is nog niet duidelijk. Eerst werd gedacht dat het verlies van dopaminerge 
cellen in de substantia nigra (“zwarte kern” in het brein) de oorzaak was van de ziekte. Inmiddels 
is bekend dat de ziekte zich niet beperkt tot één locatie in het brein, maar zich door de hersenen 
verspreidt. Er zijn genen gevonden die een rol spelen bij het ontstaan van de ziekte van Parkinson. 
Het is bekend dat het mannelijk geslacht, het drinken van water uit specifieke bronnen, stress en 
hoofdletsel de kans op de ziekte van Parkinson kan verhogen. Roken van sigaretten zou de kans op 
de ziekte van Parkinson verkleinen. De oorzaak van de ziekte is waarschijnlijk een complexe interactie 
tussen verschillende elementen en mechanismen.
In de ‘PROfiling PARKinson’s disease’ (PROPARK) studie hebben we een grote groep mensen (een 
cohort van meer dan 400 patiënten) met de ziekte van Parkinson gedurende 6 jaar gevolgd. Ieder 
jaar hebben we met vragenlijsten en meetinstrumenten onderzocht hoeveel problemen patiënten 
hadden bij elk van de symptomen. Zo konden we in kaart brengen in welke mate de patiënten 
klachten hadden op de verschillende aspecten van de ziekte en hoe het ziekteverloop was gedurende 
de zes jaar. De analyses in dit proefschrift zijn uitgevoerd op de data van het eerste jaar.
In hoofdstuk 3 hebben we onderzocht op welke wijze de klachten van de patiënten invloed 
hadden op de kwaliteit van leven, zoals de patiënten die beoordeelden op basis van hun gezondheid 
(gezondheidsgerelateerde kwaliteit van leven). We hebben hiervoor een model gemaakt. Het bleek 
dat psychosociaal welzijn een sterkere invloed had op de kwaliteit van leven dan fysiek functioneren. 
Van de symptomen van de ziekte van Parkinson had depressie de grootste invloed op de kwaliteit 
van leven, gevolgd door loopproblemen, problemen van het maagdarmstelsel (o.a. obstipatie) en 
problemen met plassen en incontinentie. Juist de niet-motorische symptomen bleken een grote 
invloed te hebben op de gezondheidsgerelateerde kwaliteit van leven. Hierbij moet wel worden 
opgemerkt dat de patiënten behandeld werden met medicijnen die met name de klachten van de 
motorische symptomen verminderen. Hierdoor kan de invloed van deze motorische symptomen op 
de kwaliteit van leven minder groot lijken. De resultaten van deze studie tonen aan dat er het van 
belang is om behandelstrategieën van de niet-motorische symptomen te onderzoeken.
In dit proefschrift is ook onderzocht hoe alle symptomen onderling met elkaar samenhangen. Dit 
hebben we gedaan voor de motorisch symptomen afzonderlijk (hoofdstuk 4), alsmede voor de 
motorische symptomen en niet-motorische symptomen samen (hoofdstuk 5). In verschillende 
modellen hebben we onderzocht welke “groepen van symptomen” sterk met elkaar samenhingen 
(factoren) binnen het totale spectrum van symptomen. Dit is interessant, omdat deze “groepen 
symptomen” of factoren waarschijnlijk worden beïnvloed door dezelfde onderliggende mechanismen. 
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We vonden factoren die samenhingen met de leeftijd, met de ernst van de ziekte, of met het gebruik 
van medicatie. Zo kunnen we beter begrijpen hoe de symptomen ontstaan en waardoor de ernst 
van de symptomen beïnvloed wordt. Daarnaast verschaffen deze factoren een objectieve basis voor 
verder onderzoek naar subtypen bij de ziekte van Parkinson. 
De ziekte van Parkinson uit zich niet bij alle patiënten hetzelfde: Sommige patiënten ervaren de eerste 
symptomen al op jonge leeftijd, terwijl anderen veel ouder zijn als de ziekte begint; er is verschil 
in de mate van bijwerkingen tussen patiënten; de klachten kunnen langzaam of snel verergeren; 
bepaalde symptomen kunnen bij sommige patiënten veel problemen geven, terwijl bij andere 
patiënten andere klachten voorop staan. Deze verscheidenheid in de uiting van de ziekte wordt 
ook wel klinische heterogeniteit genoemd. Klinische heterogeniteit kan wijzen op het bestaan van 
subgroepen van patiënten ofwel subtypen; binnen het geheel zijn groepen patiënten te herkennen 
die meer verschijnselen met elkaar gemeen hebben dan patiënten uit andere groepen.
In eerdere onderzoeken naar subtypen bij de ziekte van Parkinson werd de indeling in de subtypen 
vaak bepaald door de onderzoeker. Subtypen kunnen ook worden geïdentificeerd door middel van 
een benadering die juist door de data wordt gestuurd. In dat geval bepaalt de onderzoeker niet hoe 
de groep wordt onderverdeeld in subtypen, maar wordt gekeken naar patronen in de data. Dit is 
een meer objectieve methode. Een voorbeeld van zo een methode is clusteranalyse. In hoofdstuk 2 
hebben we systematisch gezocht naar eerdere studies die door middel van clusteranalyse subtypen 
hebben geïdentificeerd bij de ziekte van Parkinson. Zeven studies voldeden aan de criteria die aan de 
studies gesteld waren. De clusters met de karakteristieken ‘oude leeftijd bij aanvang van de ziekte 
en snelle ziekteprogressie’ en ‘jonge leeftijd bij aanvang van de ziekte en langzame ziekteprogressie’ 
werden in de meeste studies gevonden. Andere clusterprofielen waren minder consistent gevonden. 
De studies hadden echter beperkingen in de methodologie en vertoonden een onvolledige 
rapportage. Verschillen tussen studies maakte het vergelijken van de resultaten moeilijk. Studies 
met een vergelijkbare onderzoeksopzet identificeerden gelijke subtypes. Dit geeft het belang van 
een gestandaardiseerde aanpak van clusteranalyse-studies aan. Er werd geconcludeerd dat studies 
met een grondige onderzoeksopzet, die gestandaardiseerd zijn met betrekking tot variabelen in de 
analyses, het verwerken van de data en de methodetechniek de kennis van subtypen bij de ziekte 
van Parkinson kunnen vergroten. 
In hoofdstuk 6 hebben we een clusteranalyse uitgevoerd om subtypen te identificeren en deze 
vervolgens te karakteriseren. We hebben het brede spectrum van motorische- en niet-motorische 
stoornissen van de ziekte van Parkinson geanalyseerd. We hebben een ‘model-based’ clusteranalyse 
uitgevoerd op de eerste meting van de patiënten uit de PROPARK studie. We hebben vervolgens 
gekeken of we dezelfde resultaten kregen uit de gegevens van de tweede meting van ons onderzoek 
en ook in het – onafhankelijke – Spaanse cohort van de ELEP studie.
Vier subtypen konden worden geïdentificeerd in zowel ons eigen als het Spaanse cohort: Subtype 
1 was in lichte mate aangedaan op alle symptomen; subtype 2 werd voornamelijk gekarakteriseerd 
door ernstige motorische complicaties (overbeweeglijkheid en schommelingen in het effect van 
de medicatie) maar had weinig klachten bij het lopen, het denkvermogen, autonome problemen 
(vb obstipatie), hallucinaties, slaperigheid overdag en depressie (zogenaamde niet-dopaminerge 
symptomen); subtype 3 had met name ernstige niet-dopaminerge symptomen, maar geen ernstige 
motorische complicaties; subtype 4 was ernstig aangedaan op alle symptomen. De subtypes hadden 
een nagenoeg even lange ziekteduur, maar verschilden duidelijk in leeftijd, leeftijd bij aanvang 
van de ziekte, behandeling met Parkinson-medicatie en geslacht. Complexe interacties tussen 
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ziektemechanismen, behandeling, veroudering, en geslacht liggen waarschijnlijk ten grondslag aan 
deze subtypen. 
Men is zich steeds meer bewust van het belang om inzicht te krijgen in subtypen bij de ziekte 
van Parkinson, vanwege de mogelijke gevolgen enerzijds voor het inzicht in onderliggende 
ziektemechanismen en anderzijds de ontwikkeling van specifieke behandelstrategieën. Grondige 
analyses van het brede spectrum van symptomen van de ziekte van Parkinson resulteerden in 
het identificeren van verschillende groepen van symptomen (factoren) en groepen van patiënten 
(subtypen). Interessant was dat de ernst van factoren kenmerkend was voor elk van de subtypen. De 
factoren zijn dus ook van belang voor het onderzoek naar de subtypen. Hoewel de term ‘Ziekte van 
Parkinson’ lijkt te duiden op een homogene aandoening, blijkt uit vele studies, inclusief de studies in 
dit proefschrift, dat de ziekte van Parkinson verschillende klinische uitingsvormen heeft. De ‘ziekten 
van Parkinson’ is daarom misschien een beter passende naam. 
Het onderzoek naar subtypen bij de ziekte van Parkinson staat nog in de kinderschoenen. Allereerst 
moeten de resultaten van dit proefschrift worden bevestigd in andere cohorten. Ten tweede geldt 
dat in onze studie de patiënten in de subtypen een vergelijkbare gemiddelde ziekteduur hadden. Dit 
duidt op de mogelijkheid dat de subtypes ook verschillen in ziekteprogressie. Hier kunnen echter 
geen uitspraken over worden gedaan, omdat deze resultaten zijn gebaseerd op cross-sectioneel 
onderzoek (onderzoek waarbij de gegevens op één moment in de tijd worden verzameld).  Ten derde 
zouden de resultaten van dit proefschrift gevalideerd moeten worden door objectieve markers, zoals 
biomarkers. Biomarkers zijn meetbare elementen in het proces tussen de onderliggende afwijkende 
mechanismen in het lichaam en de uiting van de ziekte. Met de identificatie van biomarkers kunnen 
onderliggende ziektemechanismen worden blootgelegd. Bovendien zou mogelijk met biomarkers 
bepaald kunnen worden welke patiënten een risico hebben bepaalde symptomen te ontwikkelen, al 
voor dat deze ziekteverschijnselen zich presenteren. 
De ziekte van Parkinson is een complexe aandoening en vele elementen kunnen een rol spelen 
in de ontwikkeling van verschillende subtypen. Toekomstig onderzoek naar de ziekteprocessen 
van de ziekte van Parkinson zal zich ook moeten richten op verschillende gebieden. Een van deze 
richtingen is ‘veroudering’. De subtypen die in dit proefschrift werden gevonden verschilden 
in leeftijd. Twee subtypen met dezelfde leeftijd lieten onderling ook verschillen zien in ernst 
van de ziekte. Dus wellicht speelt niet zozeer leeftijd op zich, maar veroudering een rol in het 
ontwikkelen van symptomen. Andere studies laten ook zien dat veroudering een rol speelt bij de 
ziektemechanismen van de ziekte van Parkinson. Ook is er een samenhang gevonden tussen de 
genetica van het ouder worden en de ziekte van Parkinson. De betekenis van al deze resultaten 
moet verder onderzocht worden.
De resultaten van dit proefschrift hebben ook een betekenis voor toekomstig onderzoek naar de 
behandeling van de ziekte van Parkinson. In het PROPARK cohort bleken de niet-dopaminerge 
symptomen een grote impact te hebben op ziekte-ernst, karakterisering van subtypen en de 
kwaliteit van leven bij patiënten met de ziekte van Parkinson. Deze bevindingen wijzen op de 
behoefte aan betere behandelstrategieën van niet-dopaminerge symptomen en dit lijkt nu de 
grootste uitdaging lijkt te zijn. Een andere consequentie van de resultaten van dit proefschrift 
voor onderzoek naar de behandeling is dat, wanneer de ziekte van Parkinson wordt beschouwd 
als een homogene aandoening, subtype-specifieke risicofactoren of effecten van behandeling 
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zouden kunnen worden gemist. In toekomstig onderzoek zouden patiënten in groepen kunnen 
worden ingedeeld op basis van de subtypen, waardoor subtype-specifieke effecten kunnen 
worden geëvalueerd. 
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Dankwoord
De onderzoeken, beschreven in dit proefschrift, hadden niet kunnen worden uitgevoerd zonder de 
belangeloze inzet van vele patiënten met de ziekte van Parkinson en hun partners of verzorgers. Ik 
ben hen zeer veel dank verschuldigd.
Pap, mam, Maik, zonder jullie was dit proefschrift er niet. Jullie hebben mij alle steun gegeven die ik 
nodig had, dat zal ik niet vergeten.
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